S2k Leitlinie Autoimmune Lebererkrankungen

Zusammenfassung

Diese Leitlinie wurde unter Federführung der DGVS und mit Beteiligung benachbarter Fachgebiete erstellt und soll als praktische Hilfe für die Diagnostik und Therapie der Autoimmunen Lebererkrankungen dienen. Sie soll den aktuellen Stand der Wissenschaft darstellen, das Erkennen der Erkrankung fördern und die Behandlung der Patienten verbessern.

Abstract

The guideline was created under the leadership of the DGVS and with participation of neighbouring scientific societies and is intended as a practical aid for the diagnosis and therapy of autoimmune liver diseases. The aim is to represent the current state of science, promote the recognition of the disease and improve the treatment of patients

Schlüsselwörter

Autoimmune Hepatitis - AIH - Primär Biliäre Cholangitis - PBC - Primär Sklerosierende Cholangitis - PSC - IgG4-assoziierte Cholangitis - IAC - Lebertransplantation - Immunisierung

Key words

autoimmune hepatitis - serology - primary biliary cholangitis - primary sclerosing cholangitis - IgG4-associated cholangitis - liver transplantation - Immunization - giant cell hepatitis

• Litertur

• 1 Vergani D, Alvarez F, Bianchi FB. et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004; 41: 677-683
• 2 Feuchtinger M, Christ S, Preuss B. et al. Detection of novel non-M2-related antimitochondrial antibodies in patients with anti-M2 negative primary biliary cirrhosis. Gut 2009; 58: 983-989
• 3 European Association for the Study of the Liver. Electronic address eee. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 2015; 63: 971-1004
• 4 Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology 1993; 18: 1-9
• 5 Tan EM, Feltkamp TE, Smolen JS. et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis and rheumatism 1997; 40: 1601-1611
• 6 Czaja AJ, Morshed SA, Parveen S. et al. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology 1997; 26: 567-572
• 7 Czaja AJ, Nishioka M, Morshed SA. et al. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 1994; 107: 200-207
• 8 Parveen S, Morshed SA, Arima K. et al. Antibodies to Ro/La, Cenp-B, and snRNPs antigens in autoimmune hepatitis of North America versus Asia: patterns of immunofluorescence, ELISA reactivities, and HLA association. Digestive diseases and sciences 1998; 43: 1322-1331
• 9 Strassburg CP, Alex B, Zindy F. et al. Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases. J Hepatol 1996; 25: 859-866
• 10 Czaja AJ, Cassani F, Cataleta M. et al. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996; 24: 1068-1073
• 11 Muratori P, Muratori L, Agostinelli D. et al. Smooth muscle antibodies and type 1 autoimmune hepatitis. Autoimmunity 2002; 35: 497-500
• 12 Wiedmann KH, Melms A, Berg PA. Anti-actin antibodies of IgM and IgG class in chronic liver diseases detected by fluorometric immunoassay. Liver 1983; 3: 369-376
• 13 Bottazzo GF, Florin-Christensen A, Fairfax A. et al. Classification of smooth muscle autoantibodies detected by immunofluorescence. Journal of clinical pathology 1976; 29: 403-410
• 14 Toh BH. Smooth muscle autoantibodies and autoantigens. Clin Exp Immunol 1979; 38: 621-628
• 15 Alvarez F, Berg PA, Bianchi FB. et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938
• 16 Gregorio GV, Portmann B, Reid F. et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997; 25: 541-547
• 17 Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992; 103: 1290-1295
• 18 Gueguen M, Meunier-Rotival M, Bernard O. et al. Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J Exp Med 1988; 168: 801-806
• 19 Manns MP, Johnson EF, Griffin KJ. et al. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 1989; 83: 1066-1072
• 20 Zanger UM, Hauri HP, Loeper J. et al. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci (PNAS) 1988; 85: 8256-8260
• 21 Manns MP, Griffin KJ, Sullivan KF. et al. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991; 88: 1370-1378
• 22 Yamamoto AM, Cresteil D, Boniface O. et al. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). European journal of immunology 1993; 23: 1105-1111
• 23 Kerkar N, Ma Y, Davies ET. et al. Detection of liver kidney microsomal type 1 antibody using molecularly based immunoassays. Journal of clinical pathology 2002; 55: 906-909
• 24 Bortolotti F, Vajro P, Balli F. et al. Non-organ specific autoantibodies in children with chronic hepatitis C. J Hepatol 1996; 25: 614-620
• 25 Dalekos GN, Makri E, Loges S. et al. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece. European journal of gastroenterology & hepatology 2002; 14: 35-42
• 26 Nishioka M, Morshed SA, Kono K. et al. Frequency and significance of antibodies to P450IID6 protein in Japanese patients with chronic hepatitis C. J Hepatol 1997; 26: 992-1000
• 27 Duclos-Vallee JC, Hajoui O, Yamamoto AM. et al. Conformational epitopes on CYP2D6 are recognized by liver/kidney microsomal antibodies. Gastroenterology 1995; 108: 470-476
• 28 Klein R, Zanger UM, Berg T. et al. Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes. Clin Exp Immunol 1999; 118: 290-297
• 29 Bourdi M, Larrey D, Nataf J. et al. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. J Clin Invest 1990; 85: 1967-1973
• 30 Clemente MG, Obermayer-Straub P, Meloni A. et al. Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. The Journal of clinical endocrinology and metabolism 1997; 82: 1353-1361
• 31 Beaune P, Dansette PM, Mansuy D. et al. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci (PNAS) 1987; 84: 551-555
• 32 Crivelli O, Lavarini C, Chiaberge E. et al. Microsomal autoantibodies in chronic infection with the HBsAg associated delta (delta) agent. Clin Exp Immunol 1983; 54: 232-238
• 33 Philipp T, Durazzo M, Trautwein C. et al. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet 1994; 344: 578-581
• 34 Strassburg CP, Obermayer-Straub P, Alex B. et al. Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology 1996; 111: 1576-1586
• 35 Csepregi A, Nemesanszky E, Luettig B. et al. LKM3 autoantibodies in hepatitis C cirrhosis: a further phenomenon of the HCV-induced autoimmunity. The American journal of gastroenterology 2001; 96: 910-911
• 36 Ahonen P, Myllarniemi S, Sipila I. et al. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. The New England journal of medicine 1990; 322: 1829-1836
• 37 Clemente MG, Meloni A, Obermayer-Straub P. et al. Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology 1998; 114: 324-328
• 38 Gebre-Medhin G, Husebye ES, Gustafsson J. et al. Cytochrome P450IA2 and aromatic L-amino acid decarboxylase are hepatic autoantigens in autoimmune polyendocrine syndrome type I. FEBS letters 1997; 412: 439-445
• 39 Obermayer-Straub P, Perheentupa J, Braun S. et al. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Gastroenterology 2001; 121: 668-677
• 40 Lapierre P, Hajoui O, Homberg JC. et al. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 1999; 116: 643-649
• 41 Muratori L, Sztul E, Muratori P. et al. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology 2001; 34: 494-501
• 42 Han S, Tredger M, Gregorio GV. et al. Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease. Hepatology 1995; 21: 58-62
• 43 Muratori L, Cataleta M, Muratori P. et al. Detection of anti-liver cytosol antibody type 1 (anti-LC1) by immunodiffusion, counterimmunoelectrophoresis and immunoblotting: comparison of different techniques. Journal of immunological methods 1995; 187: 259-264
• 44 Abuaf N, Johanet C, Chretien P. et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology 1992; 16: 892-898
• 45 Lenzi M, Manotti P, Muratori L. et al. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. Gut 1995; 36: 749-754
• 46 Berg PA, Stechemesser E, Strienz J. Hypergammaglobulinämische chronisch aktive Hepatitis mit Nachweis von Leber-Pankreas-spezifischen komplementbindenden Antikörpern. Verh Dtsch Ges Inn Med 1981; 87: 921-928
• 47 Manns M, Gerken G, Kyriatsoulis A. et al. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987; 1: 292-294
• 48 Gelpi C, Sontheimer EJ, Rodriguez-Sanchez JL. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion.. Proc Natl Acad Sci (PNAS) 1992; 89: 9739-9743
• 49 Costa M, Rodriguez-Sanchez JL, Czaja AJ. et al. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients with type-1 autoimmune hepatitis. Clin Exp Immunol 2000; 121: 364-374
• 50 Volkmann M, Martin L, Baurle A. et al. Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. Hepatology 2001; 33: 591-596
• 51 Wies I, Brunner S, Henninger J. et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000; 355: 1510-1515
• 52 Ballot E, Homberg JC, Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol 2000; 33: 208-215
• 53 Czaja AJ, Manns MP. The validity and importance of subtypes in autoimmune hepatitis: a point of view. The American journal of gastroenterology 1995; 90: 1206-1211
• 54 Kanzler S, Weidemann C, Gerken G. et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999; 31: 635-640
• 55 Baeres M, Herkel J, Czaja AJ. et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002; 51: 259-264
• 56 Heneghan MA, Yeoman AD, Verma S. et al. Autoimmune hepatitis. Lancet 2013; 382: 1433-1444
• 57 Klein R, Eisenburg J, Weber P. et al. Significance and specificity of antibodies to neutrophils detected by western blotting for the serological diagnosis of primary sclerosing cholangitis. Hepatology 1991; 14: 1147-1152
• 58 Roozendaal C, de Jong MA, van den Berg AP. et al. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J Hepatol 2000; 32: 734-741
• 59 Roozendaal C, Kallenberg CG. Anti-neutrophil cytoplasm autoantibodies (ANCA) in autoimmune liver diseases. Hepatogastroenterology 1999; 46: 3034-3040
• 60 Targan SR, Landers C, Vidrich A. et al. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 1995; 108: 1159-1166
• 61 Terjung B, Herzog V, Worman HJ. et al. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 1998; 28: 332-340
• 62 Terjung B, Sohne J, Lechtenberg B. et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 2010; 59: 808-816
• 63 Claise C, Johanet C, Bouhnik Y. et al. Antineutrophil cytoplasmic autoantibodies in autoimmune liver and inflammatory bowel diseases. Liver 1996; 16: 28-34
• 64 Dalekos GN, Tsianos EV. Anti-neutrophil antibodies in chronic viral hepatitis. J Hepatol 1994; 20: 561
• 65 Zauli D, Ghetti S, Grassi A. et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 1997; 25: 1105-1107
• 66 Bansi DS, Fleming KA, Chapman RW. Antineutrophil cytoplasmic antibodies in autoimmune hepatitis. Gastroenterology 1995; 109: 2049-2050
• 67 Hausdorf G, Roggenbuck D, Feist E. et al. Autoantibodies to asialoglycoprotein receptor (ASGPR) measured by a novel ELISA--revival of a disease-activity marker in autoimmune hepatitis. Clinica chimica acta; international journal of clinical chemistry 2009; 408: 19-24
• 68 McFarlane BM, Sipos J, Gove CD. et al. Antibodies against the hepatic asialoglycoprotein receptor perfused in situ preferentially attach to periportal liver cells in the rat. Hepatology 1990; 11: 408-415
• 69 Czaja AJ, Pfeifer KD, Decker RH. et al. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Digestive diseases and sciences 1996; 41: 1733-1740
• 70 Treichel U, McFarlane BM, Seki T. et al. Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis. Gastroenterology 1994; 107: 799-804
• 71 Rigopoulou EI, Roggenbuck D, Smyk DS. et al. Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: lost and found. Autoimmunity reviews 2012; 12: 260-269
• 72 McFarlane IG. Pathogenesis of autoimmune hepatitis. Biomed Pharmacother 1999; 53: 255-263
• 73 Manns MP, Strassburg CP. Autoimmune hepatitis: clinical challenges. Gastroenterology 2001; 120: 1502-1517
• 74 Homberg JC, Abuaf N, Bernard O. et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987; 7: 1333-1339
• 75 Martini E, Abuaf N, Cavalli F. et al. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988; 8: 1662-1666
• 76 Durazzo M, Philipp T, Van Pelt FN. et al. Heterogeneity of liver-kidney microsomal autoantibodies in chronic hepatitis C and D virus infection. Gastroenterology 1995; 108: 455-462
• 77 Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. The American journal of gastroenterology 2002; 97: 413-419
• 78 Vitozzi S, Djilali-Saiah I, Lapierre P. et al. Anti-soluble liver antigen/liver-pancreas (SLA/LP) antibodies in pediatric patients with autoimmune hepatitis. Autoimmunity 2002; 35: 485-492
• 79 Gatselis NK, Zachou K, Koukoulis GK. et al. Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics. World journal of gastroenterology 2015; 21: 60-83
• 80 Berg PA, Klein R, Lindenborn-Fotinos J. et al. ATPase-associated antigen (M2): marker antigen for serological diagnosis of primary biliary cirrhosis. Lancet 1982; 2: 1423-1426
• 81 Gershwin ME, Mackay IR, Sturgess A. et al. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987; 138: 3525-3531
• 82 Oertelt S, Rieger R, Selmi C. et al. A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. Hepatology 2007; 45: 659-665
• 83 Lindenborn-Fotinos J, Baum H, Berg PA. Mitochondrial antibodies in primary biliary cirrhosis: species and nonspecies specific determinants of M2 antigen. Hepatology 1985; 5: 763-769
• 84 Fussey SP, Guest JR, James OF. et al. Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proceedings of the National Academy of Sciences of the United States of America 1988; 85: 8654-8658
• 85 Cha S, Leung PS, Gershwin ME. et al. Combinatorial autoantibodies to dihydrolipoamide acetyltransferase, the major autoantigen of primary biliary cirrhosis. Proceedings of the National Academy of Sciences of the United States of America 1993; 90: 2527-2531
• 86 Mutimer DJ, Fussey SP, Yeaman SJ. et al. Frequency of IgG and IgM autoantibodies to four specific M2 mitochondrial autoantigens in primary biliary cirrhosis. Hepatology 1989; 10: 403-407
• 87 Walker JG, Doniach D, Roitt IM. et al. Serological Tests in Diagnosis of Primary Biliary Cirrhosis. Lancet 1965; 1: 827-831
• 88 Lindor KD, Gershwin ME, Poupon R. et al. Primary Biliary Cirrhosis. Hepatology 2009; 50: 291-308
• 89 Berg PA, Klein R. Immunology of primary biliary cirrhosis. Bailliere's clinical gastroenterology 1987; 1: 675-706
• 90 Invernizzi P, Crosignani A, Battezzati PM. et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997; 25: 1090-1095
• 91 Courvalin JC, Lassoued K, Worman HJ. et al. Identification and characterization of autoantibodies against the nuclear envelope lamin B receptor from patients with primary biliary cirrhosis. J Exp Med 1990; 172: 961-967
• 92 Nickowitz RE, Worman HJ. Autoantibodies from patients with primary biliary cirrhosis recognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein Gp210. J Exp Med 1993; 178: 2237-2242
• 93 Szostecki C, Guldner HH, Netter HJ. et al. Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. J Immunol 1990; 145: 4338-4347
• 94 Invernizzi P, Selmi C, Ranftler C. et al. Antinuclear antibodies in primary biliary cirrhosis. Seminars in liver disease 2005; 25: 298-310
• 95 Wesierska-Gadek J, Penner E, Battezzati PM. et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006; 43: 1135-1144
• 96 Nakamura M, Kondo H, Mori T. et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007; 45: 118-127
• 97 Preuss B, Berg C, Dengjel J. et al. Relevance of the inner mitochondrial membrane enzyme F1F0-ATPase as an autoantigen in autoimmune liver disorders. Liver international: official journal of the International Association for the Study of the Liver 2012; 32: 249-257
• 98 Hov JR, Boberg KM, Karlsen TH. Autoantibodies in primary sclerosing cholangitis. World journal of gastroenterology 2008; 14: 3781-3791
• 99 Strassburg CP, Manns MP. Treatment of autoimmune hepatitis. Seminars in liver disease 2009; 29: 273-285
• 100 Czaja AJ, Manns MP, McFarlane IG. et al. Autoimmune hepatitis: the investigational and clinical challenges. Hepatology 2000; 31: 1194-1200
• 101 McFarlane IG. Autoimmune hepatitis: diagnostic criteria, subclassifications, and clinical features. Clin Liver Dis 2002; 6: 605-621
• 102 Chen J, Eslick GD, Weltman M. Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly. Aliment Pharmacol Ther 2014; 39: 117-124
• 103 Panayi V, Froud OJ, Vine L. et al. The natural history of autoimmune hepatitis presenting with jaundice. European journal of gastroenterology & hepatology 2014; 26: 640-645
• 104 Muratori P, Granito A, Quarneti C. et al. Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol 2009; 50: 1210-1218
• 105 Teufel A, Weinmann A, Kahaly GJ. et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol 2010; 44: 208-213
• 106 Werner M, Prytz H, Ohlsson B. et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008; 43: 1232-1240
• 107 Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992; 14: 325-331
• 108 Paredes Millan M, Chirinos Montes NJ, Martinez Apaza A. et al. The most common rheumatic diseases in patients with autoimmune liver disease in the Hospital Arzobispo Loayza from 2008-2013, Lima, Peru. Revista de gastroenterologia del Peru: organo oficial de la Sociedad de Gastroenterologia del Peru 2014; 34: 305-310
• 109 Matsumoto T, Morizane T, Aoki Y. et al. Autoimmune hepatitis in primary Sjogren's syndrome: pathological study of the livers and labial salivary glands in 17 patients with primary Sjogren's syndrome. Pathol Int 2005; 55: 70-76
• 110 Villalta D, Girolami D, Bidoli E. et al. High prevalence of celiac disease in autoimmune hepatitis detected by anti-tissue tranglutaminase autoantibodies. Journal of clinical laboratory analysis 2005; 19: 6-10
• 111 Irving KS, Sen D, Tahir H. et al. A comparison of autoimmune liver disease in juvenile and adult populations with systemic lupus erythematosus-a retrospective review of cases. Rheumatology (Oxford) 2007; 46: 1171-1173
• 112 Beisel C, Weiler-Normann C, Teufel A. et al. Association of autoimmune hepatitis and systemic lupus erythematodes: a case series and review of the literature. World journal of gastroenterology 2014; 20: 12662-12667
• 113 Boberg KM, Chapman RW, Hirschfield GM. et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011; 54: 374-385
• 114 Abdalian R, Dhar P, Jhaveri K. et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008; 47: 949-957
• 115 Lewin M, Vilgrain V, Ozenne V. et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology 2009; 50: 528-537
• 116 Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848-857
• 117 Feld JJ, Dinh H, Arenovich T. et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42: 53-62
• 118 Ngu JH, Gearry RB, Frampton CM. et al. Predictors of poor outcome in patients w ith autoimmune hepatitis: a population-based study. Hepatology 2013; 57: 2399-2406
• 119 Al-Chalabi T, Underhill JA, Portmann BC. et al. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol 2008; 48: 140-147
• 120 Gronbaek L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol 2014; 60: 612-617
• 121 Hoeroldt B, McFarlane E, Dube A. et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011; 140: 1980-1989
• 122 Schramm C, Wahl I, Weiler-Normann C. et al. Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis. J Hepatol 2014; 60: 618-624
• 123 van der Plas SM, Hansen BE, de Boer JB. et al. Generic and disease-specific health related quality of life of liver patients with various aetiologies: a survey. Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation 2007; 16: 375-388
• 124 Manns MP, Czaja AJ, Gorham JD. et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-2213
• 125 Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert opinion on drug safety 2008; 7: 319-333
• 126 Abdollahi MR, Somi MH, Faraji E. Role of international criteria in the diagnosis of autoimmune hepatitis. World journal of gastroenterology 2013; 19: 3629-3633
• 127 Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008; 48: 1540-1548
• 128 Kim BH, Kim YJ, Jeong SH. et al. Clinical features of autoimmune hepatitis and comparison of two diagnostic criteria in Korea: a nationwide, multicenter study. Journal of gastroenterology and hepatology 2013; 28: 128-134
• 129 Munoz-Espinosa L, Alarcon G, Mercado-Moreira A. et al. Performance of the international classifications criteria for autoimmune hepatitis diagnosis in Mexican patients. Autoimmunity 2011; 44: 543-548
• 130 Muratori P, Granito A, Pappas G. et al. Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients. Hepatology 2009; 49: 1782-1783 ; author reply 3
• 131 Qiu D, Wang Q, Wang H. et al. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. J Hepatol 2011; 54: 340-347
• 132 Yeoman AD, Westbrook RH, Al-Chalabi T. et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology 2009; 50: 538-545
• 133 Barreiros AP, Chiorean L, Braden B. et al. Ultrasound in rare diffuse liver disease. Zeitschrift fur Gastroenterologie 2014; 52: 1247-1256
• 134 Braden B, Faust D, Ignee A. et al. Clinical relevance of perihepatic lymphadenopathy in acute and chronic liver disease. J Clin Gastroenterol 2008; 42: 931-936
• 135 Soresi M, Bonfissuto G, Magliarisi C. et al. Ultrasound detection of abdominal lymph nodes in chronic liver diseases. A retrospective analysis. Clinical radiology 2003; 58: 372-377
• 136 Berzigotti A, Abraldes JG, Tandon P. et al. Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. J Hepatol 2010; 52: 846-853
• 137 Pfeifer L, Goertz RS, Sturm J. et al. Acoustic radiation force impulse (ARFI) and high-frequency ultrasound of the liver surface for the diagnosis of compensated liver cirrhosis. Ultraschall in Med 2014; 35: 44-50
• 138 Weiler-Normann C, Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol 2011; 55: 747-749
• 139 Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007; 46: 1138-1145
• 140 Hennes EM, Zeniya M, Czaja AJ. et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-176
• 141 Castiella A, Zapata E, Lucena MI. et al. Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. World journal of hepatology 2014; 6: 160-168
• 142 deLemos AS, Foureau DM, Jacobs C. et al. Drug-induced liver injury with autoimmune features. Seminars in liver disease 2014; 34: 194-204
• 143 Rosner S, Schad A, Kittner J. et al. Drug-induced liver injury with an autoimmune phenotype following anti-TNF Therapy – presentation of cases and review of literature. Zeitschrift fur Gastroenterologie 2014; 52: 58-63
• 144 Bjornsson ES, Gunnarsson BI, Grondal G. et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2015; 13: 602-608
• 145 Lucena MI, Kaplowitz N, Hallal H. et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol 2011; 55: 820-827
• 146 Bjornsson E, Talwalkar J, Treeprasertsuk S. et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010; 51: 2040-2048
• 147 Suzuki A, Brunt EM, Kleiner DE. et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011; 54: 931-939
• 148 Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. Journal of clinical pathology 2009; 62: 481-492
• 149 Foureau DM, Walling TL, Maddukuri V. et al. Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol 2015; 180: 40-51
• 150 Hoffman A, Rahman F, Prengel S. et al. Mini-laparoscopy in the endoscopy unit: Safety and outcomes in over one thousand patients. World journal of gastrointestinal endoscopy 2011; 3: 6-10
• 151 Rockey DC, Caldwell SH, Goodman ZD. et al. Liver biopsy. Hepatology 2009; 49: 1017-1044
• 152 Dechene A, Sowa JP, Schlattjan M. et al. Mini-laparoscopy guided liver biopsy increases diagnostic accuracy in acute liver failure. Digestion 2014; 90: 240-247
• 153 Denzer U, Helmreich-Becker I, Galle PR. et al. Liver assessment and biopsy in patients with marked coagulopathy: value of mini-laparoscopy and control of bleeding. The American journal of gastroenterology 2003; 98: 893-900
• 154 Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993; 105: 1824-1832
• 155 Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001; 34: 659-665
• 156 Ishak KG, Zimmerman HJ. Morphologic spectrum of drug-induced hepatic disease. Gastroenterology clinics of North America 1995; 24: 759-786
• 157 Luth S, Herkel J, Kanzler S. et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol 2008; 42: 926-930
• 158 Dhaliwal HK, Hoeroldt BS, Dube AK. et al. Long-Term Prognostic Significance of Persisting Histological Activity Despite Biochemical Remission in Autoimmune Hepatitis. The American journal of gastroenterology 2015; 110: 993-999
• 159 Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. The Quarterly journal of medicine 1971; 40: 159-185
• 160 Kirk AP, Jain S, Pocock S. et al. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980; 21: 78-83
• 161 Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735-737
• 162 Gleeson D, Heneghan MA. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011; 60: 1611-1629
• 163 Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 2010; 139: 58-72.e4
• 164 Soloway RD, Summerskill WH, Baggenstoss AH. et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-833
• 165 Dufour JF, Zimmermann M, Reichen J. Severe autoimmune hepatitis in patients with previous spontaneous recovery of a flare. J Hepatol 2002; 37: 748-752
• 166 Miyake Y, Iwasaki Y, Terada R. et al. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2006; 24: 1197-1205
• 167 Verma S, Gunuwan B, Mendler M. et al. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. The American journal of gastroenterology 2004; 99: 1510-1516
• 168 Summerskill WH, Korman MG, Ammon HV. et al. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975; 16: 876-883
• 169 Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981; 80: 687-692
• 170 Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 2009; 51: 161-167
• 171 Schramm C, Weiler-Normann C, Wiegard C. et al. Treatment response in patients with autoimmune hepatitis. Hepatology 2010; 52: 2247-2248
• 172 Lohse AW, Mieli-Vergani G. Autoimmune hepatitis. J Hepatol 2011; 55: 171-182
• 173 Manns MP, Woynarowski M, Kreisel W. et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198-1206
• 174 Efe C, Ozaslan E, Kav T. et al. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmunity reviews 2012; 11: 330-334
• 175 Geier A, Gartung C, Dietrich CG. et al. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World journal of gastroenterology 2003; 9: 2681-2685
• 176 Hennes EM, Oo YH, Schramm C. et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?. The American journal of gastroenterology 2008; 103: 3063-3070
• 177 Sharzehi K, Huang MA, Schreibman IR. et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Canadian journal of gastroenterology = Journal canadien de gastroenterologie 2010; 24: 588-592
• 178 Hlivko JT, Shiffman ML, Stravitz RT. et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2008; 6: 1036-1040
• 179 Zachou K, Gatselis N, Papadamou G. et al. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol 2011; 55: 636-646
• 180 Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 1996; 110: 271-274
• 181 Hubener S, Oo YH, Than NN. et al. Efficacy of 6-Mercaptopurine as Second-Line Treatment for Patients With Autoimmune Hepatitis and Azathioprine Intolerance. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2016; 14: 445-453
• 182 Weiler-Normann C, Lohse AW. Acute autoimmune hepatitis: many open questions. J Hepatol 2014; 61: 727-729
• 183 Yeoman AD, Westbrook RH, Zen Y. et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. J Hepatol 2014; 61: 876-882
• 184 Lohse AW, Gil H. Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment. J Hepatol 2011; 54: 837-839
• 185 Yeoman AD, Longhi MS, Heneghan MA. Review article: the modern management of autoimmune hepatitis. Aliment Pharmacol Ther 2010; 31: 771-787
• 186 Fernandes NF, Redeker AG, Vierling JM. et al. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. The American journal of gastroenterology 1999; 94: 241-248
• 187 Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994; 21: 1040-1047
• 188 Tannous MM, Cheng J, Muniyappa K. et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther 2011; 34: 405-407
• 189 Larsen FS, Vainer B, Eefsen M. et al. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World journal of gastroenterology 2007; 13: 3232-3236
• 190 Than NN, Wiegard C, Weiler-Normann C. et al. Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy. Scand J Gastroenterol 2016; 51: 329-336
• 191 Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998; 29: 990-993
• 192 Chatrath H, Allen L, Boyer TD. Use of sirolimus in the treatment of refractory autoimmune hepatitis. The American journal of medicine 2014; 127: 1128-1131
• 193 Ytting H, Larsen FS. Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use. Scand J Gastroenterol 2015; 50: 1025-1031
• 194 Weiler-Normann C, Schramm C, Quaas A. et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol 2013; 58: 529-534
• 195 Burak KW, Swain MG, Santodomingo-Garzon T. et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Canadian journal of gastroenterology = Journal canadien de gastroenterologie 2013; 27: 273-280
• 196 Peiseler M, Liebscher T, Sebode M. et al. Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2017 pii: S1542-3565(17)30060-5. DOI: 10.1016/j.cgh.2016.12.040
• 197 Denzer U, Arnoldy A, Kanzler S. et al. Prospective randomized comparison of minilaparoscopy and percutaneous liver biopsy: diagnosis of cirrhosis and complications. J Clin Gastroenterol 2007; 41: 103-110
• 198 Gisbert JP, Gomollón F, Cara C. et al. Thiopurine methyltransferase activity in Spain: a study of 14545 patients. Digestive diseases and sciences 2007; 52: 1262-1269
• 199 Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Digestive diseases and sciences 2006; 51: 968-975
• 200 Ferucci ED, Hurlburt KJ, Mayo MJ. et al. Azathioprine metabolite measurements are not useful in following treatment of autoimmune hepatitis in Alaska Native and other non-Caucasian people. Canadian journal of gastroenterology = Journal canadien de gastroenterologie 2011; 25: 21-27
• 201 Heneghan MA, Allan ML, Bornstein JD. et al. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006; 45: 584-591
• 202 Dhaliwal HK, Anderson R, Thornhill EL. et al. Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis. Hepatology 2012; 56: 1401-1408
• 203 Hindorf U, Jahed K, Bergquist A. et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. Journal of Hepatology 2010; 52: 106-111
• 204 Czaja AJ. Acute and acute severe (fulminant) autoimmune hepatitis. Digestive diseases and sciences 2013; 58: 897-914
• 205 Yamamoto K, Miyake Y, Ohira H. et al. Prognosis of autoimmune hepatitis showing acute presentation. Hepatol Res 2013; 43: 630-638
• 206 Karkhanis J, Verna EC, Chang MS. et al. Steroid use in acute liver failure. Hepatology (Baltimore, Md) 2014; 59: 612-621
• 207 Yeoman AD, Westbrook RH, Zen Y. et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology 2011; 53: 926-934
• 208 Lee HS, Choi GH, Joo DJ. et al. Prognostic value of model for end-stage liver disease scores in patients with fulminant hepatic failure. Transplantation proceedings 2013; 45: 2992-2994
• 209 Zhu B, You SL, Wan ZH. et al. Clinical characteristics and corticosteroid therapy in patients with autoimmune-hepatitis-induced liver failure. World journal of gastroenterology: WJG 2014; 20: 7473-7479
• 210 Westbrook RH, Yeoman AD, Kriese S. et al. Outcomes of pregnancy in women with autoimmune hepatitis. Journal of Autoimmunity 2012; 38: J239-J244
• 211 Candia L, Marquez J, Espinoza LR. Autoimmune hepatitis and pregnancy: a rheumatologist's dilemma. Semin Arthritis Rheum 2005; 35: 49-56
• 212 Aggarwal N, Chopra S, Suri V. et al. Pregnancy outcome in women with autoimmune hepatitis. Archives of Gynecology and Obstetrics 2011; 284: 19-23
• 213 Schramm C, Herkel J, Beuers U. et al. Pregnancy in autoimmune hepatitis: outcome and risk factors. The American journal of gastroenterology 2006; 101: 556-560
• 214 Terrabuio DRB, Abrantes-Lemos CP, Carrilho FJ. et al. Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. J Clin Gastroenterol 2009; 43: 350-356
• 215 Stokkeland K, Ludvigsson JF, Hultcrantz R. et al. Increased risk of preterm birth in women with autoimmune hepatitis – a nationwide cohort study. Liver international: official journal of the International Association for the Study of the Liver 2016; 36: 76-83
• 216 Heneghan MA, Norris SM, O'Grady JG. et al. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001; 48: 97-102
• 217 Samuel D, Riordan S, Strasser S. et al. Severe autoimmune hepatitis first presenting in the early post partum period. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association 2004; 2: 622-624
• 218 Werner M, Bjornsson E, Prytz H. et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding?. Scand J Gastroenterol 2007; 42: 986-991
• 219 van Gerven NM, Verwer BJ, Witte BI. et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol 2014; 49: 1245-1254
• 220 Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver International: Official Journal of the International Association for the Study of the Liver 2003; 23: 116-123
• 221 Hartl J, Ehlken H, Weiler-Normann C. et al. Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. Journal of Hepatology 2015; 62: 642-646
• 222 Czaja AJ. Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal. Digestive diseases and sciences 2010; 55: 1761-1769
• 223 Deneau M, Book LS, Guthery SL. et al. Outcome after discontinuation of immunosuppression in children with autoimmune hepatitis: a population-based study. The Journal of pediatrics 2014; 164: 714-719.e2
• 224 Roye-Green K, Willis R, Mc Morris N. et al. Autoimmune hepatitis in a Jamaican cohort spanning 40 years. Human antibodies 2013; 22: 87-93
• 225 Delgado JS, Vodonos A, Malnick S. et al. Autoimmune hepatitis in southern Israel: a 15-year multicenter study. Journal of digestive diseases 2013; 14: 611-618
• 226 Kanzler S, Lohr H, Gerken G. et al. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Zeitschrift fur Gastroenterologie 2001; 39: 339-341, 344–348
• 227 Czaja AJ, Beaver SJ, Shiels MT. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1987; 92: 215-219
• 228 De Groote J, Fevery J, Lepoutre L. Long-term follow-up of chronic active hepatitis of moderate severity. Gut 1978; 19: 510-513
• 229 Chazouilleres O, Wendum D, Serfaty L. et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 296-301
• 230 Luth S, Kanzler S, Frenzel C. et al. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. J Clin Gastroenterol 2009; 43: 75-80
• 231 Oliveira LC, Porta G, Marin ML. et al. Autoimmune hepatitis, HLA and extended haplotypes. Autoimmunity reviews 2011; 10: 189-193
• 232 Ma Y, Bogdanos DP, Hussain MJ. et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006; 130: 868-882
• 233 Montano-Loza AJ, Shums Z, Norman GL. et al. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver international: official journal of the International Association for the Study of the Liver 2012; 32: 85-92
• 234 Nierhoff J, Chavez Ortiz AA, Herrmann E. et al. The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis. European radiology 2013; 23: 3040-3053
• 235 Ferraioli G, Filice C, Castera L. et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver. Ultrasound in medicine & biology 2015; 41: 1161-1179
• 236 Hartl J, Denzer U, Ehlken H. et al. Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis. J Hepatol 2016; 65: 769-775
• 237 Abdollahi M, Pouri A, Ghojazadeh M. et al. Non-invasive serum fibrosis markers: A study in chronic hepatitis. BioImpacts: BI 2015; 5: 17-23
• 238 Teufel A, Weinmann A, Centner C. et al. Hepatocellular carcinoma in patients with autoimmune hepatitis. World journal of gastroenterology 2009; 15: 578-582
• 239 Danielsson Borssen A, Almer S, Prytz H. et al. Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis--a long-term follow-up study in 634 Swedish patients. Scand J Gastroenterol 2015; 50: 217-223
• 240 Werner M, Almer S, Prytz H. et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol 2009; 50: 388-393
• 241 Yeoman AD, Al-Chalabi T, Karani JB. et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. Hepatology 2008; 48: 863-870
• 242 Ngu JH, Gearry RB, Frampton CM. et al. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology 2012; 55: 522-529
• 243 Wong RJ, Gish R, Frederick T. et al. Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Digestive diseases and sciences 2011; 56: 578-585
• 244 Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. The American journal of gastroenterology 2008; 103: 1944-1951
• 245 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022
• 246 Zhang H, Yang J, Zhu R. et al. Combination therapy of ursodeoxycholic acid and budesonide for PBC-AIH overlap syndrome: a meta-analysis. Drug Des Devel Ther 2015; 9: 567-574
• 247 EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of hepatology 2012; 56: 908-943
• 248 Greten TF, Malek NP, Schmidt S. et al. Diagnosis of and therapy for hepatocellular carcinoma. Zeitschrift fur Gastroenterologie 2013; 51: 1269-1326
• 249 Tang R, Chen H, Miao Q. et al. The cumulative effects of known susceptibility variants to predict primary biliary cirrhosis risk. Genes and immunity 2015; 16: 193-198
• 250 Bianchi I, Carbone M, Lleo A. et al. Genetics and epigenetics of primary biliary cirrhosis. Seminars in liver disease 2014; 34: 255-264
• 251 Lammert C, Nguyen DL, Juran BD. et al. Questionnaire based assessment of risk factors for primary biliary cirrhosis. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2013; 45: 589-594
• 252 Wahl I, Feige A, Lowe B. et al. Primary biliary "cirrhosis": time to replace a misnomer. Hepatology 2015; 61: 1091
• 253 Heathcote EJ. Primary biliary cirrhosis: historical perspective. Clin Liver Dis 2003; 7: 735-740
• 254 Beuers U, Gershwin ME, Gish RG. et al. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. J Hepatol 2015; 63: 1285-1287
• 255 Bowlus CL, Gershwin ME. The diagnosis of primary biliary cirrhosis. Autoimmunity reviews 2014; 13: 441-444
• 256 Ali AH, Carey EJ, Lindor KD. Diagnosis and management of primary biliary cirrhosis. Expert review of clinical immunology 2014; 10: 1667-1678
• 257 Boonstra K, Culver EL, de Buy Wenniger LM. et al. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology 2014; 59: 1954-1963
• 258 Griffiths L, Dyson JK, Jones DE. The new epidemiology of primary biliary cirrhosis. Seminars in liver disease 2014; 34: 318-328
• 259 Baldursdottir TR, Bergmann OM, Jonasson JG. et al. The epidemiology and natural history of primary biliary cirrhosis: a nationwide population-based study. European journal of gastroenterology & hepatology 2012; 24: 824-830
• 260 Righi S, Fiorini E, De Molo C. et al. ARFI elastography in patients with chronic autoimmune liver diseases: A preliminary study. Journal of ultrasound 2012; 15: 226-231
• 261 Tsochatzis EA, Gurusamy KS, Ntaoula S. et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011; 54: 650-659
• 262 Zhang DK, Chen M, Liu Y. et al. Acoustic radiation force impulse elastography for non-invasive assessment of disease stage in patients with primary biliary cirrhosis: A preliminary study. Clinical radiology 2014; 69: 836-840
• 263 Corpechot C, Carrat F, Poujol-Robert A. et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012; 56: 198-208
• 264 Pang JX, Zimmer S, Niu S. et al. Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease. PloS one 2014; 9: e95776
• 265 Singh S, Fujii LL, Murad MH. et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2013; 11: 1573-1584.e1–2 ; quiz e88–9
• 266 Kubota J, Ikeda F, Terada R. et al. Mortality rate of patients with asymptomatic primary biliary cirrhosis diagnosed at age 55 years or older is similar to that of the general population. Journal of gastroenterology 2009; 44: 1000-1006
• 267 Corpechot C, Wendum D. Primary biliary cirrhosis: is there still a place for histological evaluation?. Clin Res Hepatol Gastroenterol 2013; 37: 556-558
• 268 Nakanuma Y. Primary biliary cirrhosis: is there still a place for histological evaluation?. Clin Res Hepatol Gastroenterol 2014; 38: e1-e2
• 269 Beuers UH, Boberg KM, Chapman RW. et al. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267
• 270 Khan FM, Komarla AR, Mendoza PG. et al. Keratin 19 demonstration of canal of Hering loss in primary biliary cirrhosis: "minimal change PBC"?. Hepatology 2013; 57: 700-707
• 271 Kakuda Y, Harada K, Nakanuma Y. Canals of Hering loss relates to the progression of the histological stages of primary biliary cirrhosis. Journal of clinical pathology 2015; 68: 141-147
• 272 Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Archiv A, Pathological anatomy and histology 1978; 379: 103-112
• 273 Scheuer PJ. Primary biliary cirrhosis: diagnosis, pathology and pathogenesis. Postgrad Med J 1983; 59: 106-115
• 274 Hiramatsu K, Aoyama H, Zen Y. et al. Proposal of a new staging and grading system of the liver for primary biliary cirrhosis. Histopathology 2006; 49: 466-478
• 275 Nakanuma Y, Zen Y, Harada K. et al. Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement. Pathol Int 2010; 60: 167-174
• 276 Kakuda Y, Harada K, Sawada-Kitamura S. et al. Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems. Hum Pathol 2013; 44: 1107-1117
• 277 Wendum D, Boelle PY, Bedossa P. et al. Primary biliary cirrhosis: proposal for a new simple histological scoring system. Liver international: official journal of the International Association for the Study of the Liver 2015; 35: 652-659
• 278 Gaya DR, Thorburn D, Oien KA. et al. Hepatic granulomas: a 10 year single centre experience. Journal of clinical pathology 2003; 56: 850-853
• 279 Paul S, Sepehr GJ, Weinstein B. et al. Co-occurrence of idiopathic granulomatous hepatitis and primary biliary cirrhosis. Digestive diseases and sciences 2014; 59: 2831-2835
• 280 Modaresi Esfeh J, Culver D, Plesec T. et al. Clinical presentation and protocol for management of hepatic sarcoidosis. Expert Rev Gastroenterol Hepatol 2015; 9: 349-358
• 281 Egritas O, Sari S, Dalgic B. et al. Granulomatous hepatitis, perihepatic lymphadenopathies, and autoantibody positivity: an unusual association in a child with hepatitis C. Eur J Pediatr 2009; 168: 275-279
• 282 Ozaras R, Tahan V, Mert A. et al. The prevalence of hepatic granulomas in chronic hepatitis C. J Clin Gastroenterol 2004; 38: 449-452
• 283 Farah M, Al Rashidi A, Owen DA. et al. Granulomatous hepatitis associated with etanercept therapy. J Rheumatol 2008; 35: 349-351
• 284 Fiel MI, Shukla D, Saraf N. et al. Development of hepatic granulomas in patients receiving pegylated interferon therapy for recurrent hepatitis C virus post liver transplantation. Transpl Infect Dis 2008; 10: 184-189
• 285 Ben Mustapha N, Karoui S, Serghini M. et al. Frequency and predictive factors of granulomatous hepatitis in patients with peritoneal tuberculosis. Tunis Med 2009; 87: 382-385
• 286 Shoaran M, Najafi M, Jalilian R. et al. Granulomatous hepatitis as a rare complication of Bacillus Calmette-Guerin vaccination. Ann Saudi Med 2013; 33: 627-629
• 287 Delimpoura V, Samitas K, Vamvakaris I. et al. Concurrent granulomatous hepatitis, pneumonitis and sepsis as a complication of intravesical BCG immunotherapy. BMJ Case Rep 2013; 2013 pii: bcr2013200624. DOI: 10.1136/bcr-2013-200624.
• 288 Desmet M, Moubax K, Haerens M. Multiple organ failure and granulomatous hepatitis following intravesical bacillus Calmette-Guerin instillation. Acta Clin Belg 2012; 67: 367-369
• 289 Rustagi T, Rai M, Alekshun TJ. Granulomatous hepatitis from disseminated Mycobacterium bovis infection: shift of an intended local towards a detrimental systemic infection. Trop Gastroenterol 2011; 32: 157-158
• 290 Trevenzoli M, Cattelan AM, Marino F. et al. Sepsis and granulomatous hepatitis after bacillus Calmette-Guerin intravesical installation. J Infect 2004; 48: 363-364
• 291 Leebeek FW, Ouwendijk RJ, Kolk AH. et al. Granulomatous hepatitis caused by Bacillus Calmette-Guerin (BCG) infection after BCG bladder instillation. Gut 1996; 38: 616-618
• 292 Gao CQ, Mithani R, Leya J. et al. Granulomatous hepatitis, choroiditis and aortoduodenal fistula complicating intravesical Bacillus Calmette-Guerin therapy: Case report. BMC Infect Dis 2011; 11: 260
• 293 Hristea A, Neacsu A, Ion DA. et al. BCG-related granulomatous hepatitis. Pneumologia 2007; 56: 32-34
• 294 Fallahzadeh MK, Fallahzadeh MA, Mojtahedi Y. et al. Granulomatous liver involvement in a child with systemic lupus erythematosus: a case report and review of the literature. Lupus 2013; 22: 1388-1393
• 295 Rojas-Feria M, Castro M, Suarez E. et al. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World journal of gastroenterology: WJG 2013; 19: 7327-7340
• 296 Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1598-1619
• 297 Aguilar-Olivos N, del Carmen Manzano-Robleda M, Gutierrez-Grobe Y. et al. Granulomatous hepatitis caused by Q fever: a differential diagnosis of fever of unknown origin. Ann Hepatol 2013; 12: 138-141
• 298 Lai CH, Lin JN, Chang LL. et al. Circulating cytokines and procalcitonin in acute Q fever granulomatous hepatitis with poor response to antibiotic and short-course steroid therapy: a case report. BMC Infect Dis 2010; 10: 193
• 299 Cone LA, Curry N, Shaver P. et al. Q fever in the Southern California desert: epidemiology, clinical presentation and treatment. Am J Trop Med Hyg 2006; 75: 29-32
• 300 VanderHeyden TR, Yong SL, Breitschwerdt EB. et al. Granulomatous hepatitis due to Bartonella henselae infection in an immunocompetent patient. BMC Infect Dis 2012; 12: 17
• 301 Bonatti H, Mendez J, Guerrero I. et al. Disseminated Bartonella infection following liver transplantation. Transpl Int 2006; 19: 683-687
• 302 Holl-Ulrich K, Klass M. Wegener s granulomatosis with granulomatous liver involvement. Clin Exp Rheumatol 2010; 28: 88-89
• 303 Tahan V, Ozaras R, Lacevic N. et al. Prevalence of hepatic granulomas in chronic hepatitis B. Digestive diseases and sciences 2004; 49: 1575-1577
• 304 Kanbay M, Altundag K, Gur G. et al. Non-Hodgkin's lymphoma presenting with granulomatous hepatitis and hemophagocytosis. Leuk Lymphoma 2006; 47: 767-769
• 305 Zanchi AC, Gingold AR, Theise ND. et al. Necrotizing granulomatous hepatitis as an unusual manifestation of Lyme disease. Digestive diseases and sciences 2007; 52: 2629-2632
• 306 Miller EB, Shichmanter R, Friedman JA. et al. Granulomatous hepatitis and Sjogren's syndrome: an association. Semin Arthritis Rheum 2006; 36: 153-158
• 307 Floreani A, Franceschet I, Cazzagon N. Primary biliary cirrhosis: overlaps with other autoimmune disorders. Seminars in liver disease 2014; 34: 352-360
• 308 Rigamonti C, Shand LM, Feudjo M. et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006; 55: 388-394
• 309 Matsumoto T, Kobayashi S, Shimizu H. et al. The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. Liver 2000; 20: 366-373
• 310 Inoue K, Hirohara J, Nakano T. et al. Prediction of prognosis of primary biliary cirrhosis in Japan. Liver 1995; 15: 70-77
• 311 Marasini B, Gagetta M, Rossi V. et al. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. Annals of the rheumatic diseases 2001; 60: 1046-1049
• 312 Heathcote J. The clinical expression of primary biliary cirrhosis. Seminars in liver disease 1997; 17: 23-33
• 313 Yamagiwa S, Kamimura H, Takamura M. et al. Autoantibodies in primary biliary cirrhosis: recent progress in research on the pathogenetic and clinical significance. World journal of gastroenterology: WJG 2014; 20: 2606-2612
• 314 Caldwell SH, Leung PS, Spivey JR. et al. Antimitochondrial antibodies in kindreds of patients with primary biliary cirrhosis: antimitochondrial antibodies are unique to clinical disease and are absent in asymptomatic family members. Hepatology 1992; 16: 899-905
• 315 Zografos TA, Gatselis N, Zachou K. et al. Primary biliary cirrhosis-specific autoantibodies in first degree relatives of Greek primary biliary cirrhosis patients. World journal of gastroenterology: WJG 2012; 18: 4721-4728
• 316 Lazaridis KN, Juran BD, Boe GM. et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 2007; 46: 785-792
• 317 Yanagisawa M, Takagi H, Takahashi H. et al. Familial clustering and genetic background of primary biliary cirrhosis in Japan. Digestive diseases and sciences 2010; 55: 2651-2658
• 318 Mantaka A, Koulentaki M, Chlouverakis G. et al. Primary biliary cirrhosis in a genetically homogeneous population: disease associations and familial occurrence rates. BMC Gastroenterol 2012; 12: 110
• 319 Newton JL, Elliott C, Frith J. et al. Functional capacity is significantly impaired in primary biliary cirrhosis and is related to orthostatic symptoms. European journal of gastroenterology & hepatology 2011; 23: 566-572
• 320 Mells GF, Pells G, Newton JL. et al. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology 2013; 58: 273-283
• 321 Untas A, Boujut E, Corpechot C. et al. Quality of life and illness perception in primary biliary cirrhosis: a controlled cross-sectional study. Clin Res Hepatol Gastroenterol 2015; 39: 52-58
• 322 Griffiths L, Jones DE. Pathogenesis of primary biliary cirrhosis and its fatigue. Dig Dis 2014; 32: 615-625
• 323 Hollingsworth KG, Newton JL, Robinson L. et al. Loss of capacity to recover from acidosis in repeat exercise is strongly associated with fatigue in primary biliary cirrhosis. Journal of hepatology 2010; 53: 155-161
• 324 Pells G, Mells GF, Carbone M. et al. The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort. Journal of hepatology 2013; 59: 67-73
• 325 Beuers U, Kremer AE, Bolier R. et al. Pruritus in cholestasis: facts and fiction. Hepatology 2014; 60: 399-407
• 326 Poupon RE, Chretien Y, Poupon R. et al. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology 1993; 17: 599-604
• 327 Poupon RE, Lindor KD, Cauch-Dudek K. et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884-890
• 328 Poupon RE, Balkau B, Eschwege E. et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. The New England journal of medicine 1991; 324: 1548-1554
• 329 Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. The New England journal of medicine 1994; 330: 1342-1347
• 330 Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006; 130: 715-720
• 331 Toklu HZ, Dumlu MU, Sehirli O. et al. Pomegranate peel extract prevents liver fibrosis in biliary-obstructed rats. J Pharm Pharmacol 2007; 59: 1287-1295
• 332 Hung GD, Li PC, Lee HS. et al. Green tea extract supplementation ameliorates CCl4-induced hepatic oxidative stress, fibrosis, and acute-phase protein expression in rat. J Formos Med Assoc 2012; 111: 550-559
• 333 Dulundu E, Ozel Y, Topaloglu U. et al. Grape seed extract reduces oxidative stress and fibrosis in experimental biliary obstruction. Journal of gastroenterology and hepatology 2007; 22: 885-892
• 334 Lee TY, Chang HH, Chen JH. et al. Herb medicine Yin-Chen-Hao-Tang ameliorates hepatic fibrosis in bile duct ligation rats. J Ethnopharmacol 2007; 109: 318-324
• 335 Angulo P, Patel T, Jorgensen RA. et al. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000; 32: 897-900
• 336 Kuiper EM, Hansen BE, de Vries RA. et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136: 1281-1287
• 337 Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. Journal of hepatology 2011; 55: 1361-1367
• 338 Kuiper EM, Hansen BE, Lesterhuis W. et al. The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis. Clin Res Hepatol Gastroenterol 2011; 35: 29-33
• 339 Lammers WJ, van Buuren HR, Hirschfield GM. et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014; 147: 1338-1349 e5 ; quiz e15
• 340 Fang YQ, Lv DX, Jia W. et al. Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis. Medicine 2014; 93: e104
• 341 Rautiainen H, Karkkainen P, Karvonen AL. et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 2005; 41: 747-752
• 342 Angulo P, Batts KP, Jorgensen RA. et al. Oral budesonide in the treatment of primary sclerosing cholangitis. The American journal of gastroenterology 2000; 95: 2333-2337
• 343 Trauner M, Halilbasic E, Kazemi-Shirazi L. et al. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies. Dig Dis 2014; 32: 631-636
• 344 Cheung AC, Lapointe-Shaw L, Kowgier M. et al. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther 2016; 43: 283-293
• 345 Hirschfield GM, Mason A, Luketic V. et al. Efficacy of obeticholic Acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic Acid. Gastroenterology 2015; 148: 751-761 e8
• 346 Nevens F, Andreone P, Mazzella G. et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. The New England journal of medicine 2016; 375: 631-643
• 347 Myers RP, Swain MG, Lee SS. et al. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. The American journal of gastroenterology 2013; 108: 933-941
• 348 Tsuda M, Moritoki Y, Lian ZX. et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology 2012; 55: 512-521
• 349 Quarneti C, Muratori P, Lalanne C. et al. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver international: official journal of the International Association for the Study of the Liver 2015; 35: 636-641
• 350 Poupon R, Chazouilleres O, Corpechot C. et al. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006; 44: 85-90
• 351 Beuers U, Rust C. Overlap syndromes. Seminars in liver disease 2005; 25: 311-320
• 352 Floreani A, Farinati F. Risk factors associated with hepatocellular carcinoma in primary biliary cirrhosis. Hepatology 2013; 58: 1520-1521
• 353 Harada K, Hirohara J, Ueno Y. et al. Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan. Hepatology 2013; 57: 1942-1949
• 354 Trivedi PJ, Lammers WJ, van Buuren HR. et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut 2015; 65: 321-329
• 355 Liang Y, Yang Z, Zhong R. Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis. Hepatology 2012; 56: 1409-1417
• 356 Floreani A, Spinazze A, Caballeria L. et al. Extrahepatic malignancies in primary biliary cirrhosis: a comparative study at two European centers. Clin Rev Allergy Immunol 2015; 48: 254-262
• 357 Carbone M, Mells G, Pells G. et al. Sex and Age Are Determinants of the Clinical Phenotype of Primary Biliary Cirrhosis and Response to Ursodeoxycholic Acid. Gastroenterology 2013; 144: 560-569
• 358 Nakamura M, Kondo H, Tanaka A. et al. Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Japanese patients with primary biliary cirrhosis. Hepatol Res 2015; 45: 846-855
• 359 Joshita S, Umemura T, Ota M. et al. AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis. J Hepatol 2014; 61: 1443-1445
• 360 Ikeda F, Okamoto R, Baba N. et al. Prevalence and associated factors with esophageal varices in early primary biliary cirrhosis. Journal of gastroenterology and hepatology 2012; 27: 1320-1328
• 361 Parikh-Patel A, Gold E, Utts J. et al. The association between gravidity and primary biliary cirrhosis. Ann Epidemiol 2002; 12: 264-272
• 362 Floreani A, Infantolino C, Franceschet I. et al. Pregnancy and primary biliary cirrhosis: a case-control study. Clinical reviews in allergy & immunology 2015; 48: 236-242
• 363 Trivedi PJ, Kumagi T, Al-Harthy N. et al. Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2014; 12: 1179-1185 e1
• 364 Efe C, Kahramanoglu-Aksoy E, Yilmaz B. et al. Pregnancy in women with primary biliary cirrhosis. Autoimmunity reviews 2014; 13: 931-935
• 365 Poupon R, Chretien Y, Chazouilleres O. et al. Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis. Journal of Hepatology 2005; 42: 418-419
• 366 Wellge BE, Sterneck M, Teufel A. et al. Pregnancy in primary sclerosing cholangitis. Gut 2011; 60: 1117-1121
• 367 Bacq Y, Sentilhes L, Reyes HB. et al. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterology 2012; 143: 1492-1501
• 368 Vitek L, Zelenkova M, Bruha R. Safe use of ursodeoxycholic acid in a breast-feeding patient with primary biliary cirrhosis. Dig Liver Dis 2010; 42: 911-912
• 369 Kremer AE, Feramisco J, Reeh PW. et al. Receptors, cells and circuits involved in pruritus of systemic disorders. Biochim Biophys Acta 2014; 1842: 869-892
• 370 Kremer AE, van Dijk R, Leckie P. et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 2012; 56: 1391-1400
• 371 Gong Y, Huang Z, Christensen E. et al. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. The American journal of gastroenterology 2007; 102: 1799-1807
• 372 Jones EA, Bergasa NV. Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis. Can J Gastroenterol 2000; 14: 33-40
• 373 Kuiper EM, van Erpecum KJ, Beuers U. et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: Results of a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52: 1334-1340
• 374 Tandon P, Rowe BH, Vandermeer B. et al. The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007; 102: 1528-1536 . Epub 2007 Mar 31
• 375 Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. The American journal of gastroenterology 2003; 98: 2736-2741
• 376 Mayo MJ, Handem I, Saldana S. et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007; 45: 666-674
• 377 Lens S, Leoz M, Nazal L. et al. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver international: official journal of the International Association for the Study of the Liver 2014; 34: 197-203
• 378 Pares A, Herrera M, Aviles J. et al. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol 2010; 53: 307-312
• 379 Pusl T, Denk GU, Parhofer KG. et al. Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. J Hepatol 2006; 45: 887-891
• 380 Stapelbroek JM, van Erpecum KJ, Klomp LW. et al. Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. Hepatology 2006; 43: 51-53
• 381 Beuers U, Gerken G, Pusl T. Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. Hepatology 2006; 44: 280-281
• 382 Hegade VS, Krawczyk M, Kremer AE. et al. The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study. Aliment Pharmacol Ther 2016; 43: 294-302
• 383 Decock S, Roelandts R, Steenbergen WV. et al. Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study. Journal of hepatology 2012; 57: 637-641
• 384 EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267
• 385 Newton JL, Bhala N, Burt J. et al. Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure. Journal of hepatology 2006; 44: 776-783
• 386 Anderson K, Jones DE, Wilton K. et al. Restless leg syndrome is a treatable cause of sleep disturbance and fatigue in primary biliary cirrhosis. Liver international: official journal of the International Association for the Study of the Liver 2013; 33: 239-243
• 387 Newton JL, Jones DE. Managing systemic symptoms in chronic liver disease. Journal of hepatology 2012; 56 (Suppl. 01) 46-55
• 388 Jones DE, Newton JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Alimentary pharmacology & therapeutics 2007; 25: 471-476
• 389 Hardy T, MacDonald C, Jones DE. et al. A follow-up study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Liver international: official journal of the International Association for the Study of the Liver 2010; 30: 1551-1552
• 390 Ian Gan S, de Jongh M, Kaplan MM. Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. Digestive diseases and sciences 2009; 54: 2242-2246
• 391 Mavragani CP, Moutsopoulos HM. Conventional therapy of Sjogren's syndrome. Clinical reviews in allergy & immunology 2007; 32: 284-291
• 392 Ramos-Casals M, Tzioufas AG, Stone JH. et al. Treatment of primary Sjogren syndrome: a systematic review. Jama 2010; 304: 452-460
• 393 Sheppard Jr JD, Singh R, McClellan AJ. et al. Long-term Supplementation With n-6 and n-3 PUFAs Improves Moderate-to-Severe Keratoconjunctivitis Sicca: A Randomized Double-Blind Clinical Trial. Cornea 2013; 32: 1297-1304
• 394 Beirao JM, Matos ME, Beirao IB. et al. Topical cyclosporine for severe dry eye disease in liver-transplanted Portuguese patients with familial amyloidotic polyneuropathy (ATTRV30M). Eur J Ophthalmol 2013; 23: 156-163
• 395 Boynton GE, Raoof D, Niziol LM. et al. Prospective Randomized Trial Comparing Efficacy of Topical Loteprednol Etabonate 0.5% Versus Cyclosporine-A 0.05% for Treatment of Dry Eye Syndrome Following Hematopoietic Stem Cell Transplantation. Cornea 2015; 34: 725-732
• 396 Mang FW, Michieletti P, O'Rourke K. et al. Primary biliary cirrhosis, sicca complex, and dysphagia. Dysphagia 1997; 12: 167-170
• 397 Menon KV, Angulo P, Weston S. et al. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. Journal of hepatology 2001; 35: 316-323
• 398 Pares A, Guanabens N. Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. Clin Liver Dis 2008; 12: 407-424; x
• 399 Guanabens N, Monegal A, Cerda D. et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology 2013; 58: 2070-2078
• 400 Guanabens N, Pares A, Ros I. et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. The American journal of gastroenterology 2003; 98: 2268-2274
• 401 Zein CO, Jorgensen RA, Clarke B. et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005; 42: 762-771
• 402 Boone RH, Cheung AM, Girlan LM. et al. Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. Digestive diseases and sciences 2006; 51: 1103-1112
• 403 Rudic JS, Poropat G, Krstic MN. et al. Hormone replacement for osteoporosis in women with primary biliary cirrhosis. Cochrane Database Syst Rev 2011; DOI: CD009146.
• 404 Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis 2007; 194: 293-299
• 405 Chang PY, Lu SC, Su TC. et al. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res 2004; 45: 2116-2122
• 406 Allocca M, Crosignani A, Gritti A. et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut 2006; 55: 1795-1800
• 407 Ungprasert P, Wijarnpreecha K, Ahuja W. et al. Coronary artery disease in primary biliary cirrhosis: A systematic review and meta-analysis of observational studies. Hepatol Res 2014; 45: 1055-1061
• 408 Wang C, Zhao P, Liu W. Risk of incident coronary artery disease in patients with primary biliary cirrhosis. Int J Clin Exp Med 2014; 7: 2921-2924
• 409 Poupon RE, Ouguerram K, Chretien Y. et al. Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology 1993; 17: 577-582
• 410 Cash WJ, O'Neill S, O'Donnell ME. et al. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver international: official journal of the International Association for the Study of the Liver 2013; 33: 1166-1174
• 411 Kuiper EM, Zondervan PE, van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2010; 8: 530-534
• 412 Lohse AW, zum Buschenfelde KH, Franz B. et al. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999; 29: 1078-1084
• 413 Bambha K, Kim WR, Talwalkar J. et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125: 1364-1369
• 414 Broome U, Olsson R, Loof L. et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610-615
• 415 Lindkvist B, Benito de Valle M, Gullberg B. et al. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 52: 571-577
• 416 Tischendorf JJ, Hecker H, Kruger M. et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. The American journal of gastroenterology 2007; 102: 107-114
• 417 Chapman RW, Arborgh BA, Rhodes JM. et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21: 870-877
• 418 Weismuller TJ, Trivedi PJ, Bergquist A. et al. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology 2017; 152: 1975-1984
• 419 Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012; 56: 1181-1188
• 420 Boonstra K, Weersma RK, van Erpecum KJ. et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013; 58: 2045-2055
• 421 Benito de Valle M, Rahman M, Lindkvist B. et al. Factors that reduce health-related quality of life in patients with primary sclerosing cholangitis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2012; 10: 769-775 e2
• 422 Balasubramaniam K, Wiesner RH, LaRusso NF. Primary sclerosing cholangitis with normal serum alkaline phosphatase activity. Gastroenterology 1988; 95: 1395-1398
• 423 Lindstrom L, Hultcrantz R, Boberg KM. et al. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2013; 11: 841-846
• 424 Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Seminars in liver disease 1991; 11: 31-39
• 425 Wiesner RH, Grambsch PM, Dickson ER. et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989; 10: 430-436
• 426 Loftus Jr EV, Harewood GC, Loftus CG. et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91-96
• 427 Gizard E, Ford AC, Bronowicki JP. et al. Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2014; 40: 3-15
• 428 Rasmussen HH, Fallingborg JF, Mortensen PB. et al. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol 1997; 32: 604-610
• 429 Lunder AK, Hov JR, Borthne A. et al. Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel Disease. Gastroenterology 2016; 151: 660-669 e4
• 430 Aadland E, Schrumpf E, Fausa O. et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 1987; 22: 655-664
• 431 Schrumpf E, Elgjo K, Fausa O. et al. Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol 1980; 15: 689-697
• 432 Sinakos E, Samuel S, Enders F. et al. Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. Inflamm Bowel Dis 2013; 19: 1004-1049
• 433 Verdonk RC, Dijkstra G, Haagsma EB. et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant 2006; 6: 1422-1429
• 434 Faubion Jr WA, Loftus EV, Sandborn WJ. et al. Pediatric "PSC-IBD": a descriptive report of associated inflammatory bowel disease among pediatric patients with psc. J Pediatr Gastroenterol Nutr 2001; 33: 296-300
• 435 Claessen MM, Lutgens MW, van Buuren HR. et al. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 2009; 15: 1331-1336
• 436 Soetikno RM, Lin OS, Heidenreich PA. et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointestinal endoscopy 2002; 56: 48-54
• 437 Claessen MM, Vleggaar FP, Tytgat KM. et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50: 158-164
• 438 Haapamaki J, Tenca A, Sintonen H. et al. Health-related quality of life among patients with primary sclerosing cholangitis. Liver international: official journal of the International Association for the Study of the Liver 2015; 35: 2194-2201
• 439 Ananthakrishnan AN, Beaulieu DB, Ulitsky A. et al. Does primary sclerosing cholangitis impact quality of life in patients with inflammatory bowel disease?. Inflamm Bowel Dis 2010; 16: 494-500
• 440 Gotthardt DN, Rupp C, Bruhin M. et al. Pruritus is associated with severely impaired quality of life in patients with primary sclerosing cholangitis. European journal of gastroenterology & hepatology 2014; 26: 1374-1379
• 441 Gross CR, Malinchoc M, Kim WR. et al. Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology 1999; 29: 356-364
• 442 Saldeen K, Friman S, Olausson M. et al. Follow-up after liver transplantation for primary sclerosing cholangitis: effects on survival, quality of life, and colitis. Scand J Gastroenterol 1999; 34: 535-540
• 443 Bjornsson E, Boberg KM, Cullen S. et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 2002; 51: 731-735
• 444 Naess S, Bjornsson E, Anmarkrud JA. et al. Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease. Liver international: official journal of the International Association for the Study of the Liver 2014; 34: 1488-1495
• 445 Corpechot C, Gaouar F, El Naggar A. et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology 2014; 146: 970-979 ; quiz e15–16
• 446 Ehlken H, Wroblewski R, Corpechot C. et al. Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis. PloS one 2016; 11: e0164224
• 447 Bjornsson E, Chari S, Silveira M. et al. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther 2011; 18: 198-205
• 448 Dave M, Elmunzer BJ, Dwamena BA. et al. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology 2010; 256: 387-396
• 449 Weber C, Kuhlencordt R, Grotelueschen R. et al. Magnetic resonance cholangiopancreatography in the diagnosis of primary sclerosing cholangitis. Endoscopy 2008; 40: 739-745
• 450 Jhaveri K, Cleary S, Audet P. et al. Consensus statements from a multidisciplinary expert panel on the utilization and application of a liver-specific MRI contrast agent (gadoxetic acid). Am J Roentgenol American journal of roentgenology 2015; 204: 498-509
• 451 Hirche TO, Russler J, Braden B. et al. Sonographic detection of perihepatic lymphadenopathy is an indicator for primary sclerosing cholangitis in patients with inflammatory bowel disease. Int J Colorectal Dis 2004; 19: 586-594
• 452 Kirchner GI, Tischendorf JJ, Bleck J. et al. Perihilar lymph nodes in patients with primary sclerosing cholangitis with and without cholangiocellular carcinoma. Scand J Gastroenterol 2008; 43: 1366-1370
• 453 Buckles DC, Lindor KD, Larusso NF. et al. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. The American journal of gastroenterology 2002; 97: 1138-1142
• 454 Eaton JE, Thackeray EW, Lindor KD. Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. The American journal of gastroenterology 2012; 107: 431-439
• 455 Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol 2008; 48: 598-605
• 456 van de Meeberg PC, Portincasa P, Wolfhagen FH. et al. Increased gall bladder volume in primary sclerosing cholangitis. Gut 1996; 39: 594-599
• 457 Lammert F, Neubrand MW, Bittner R. et al. S3-guidelines for diagnosis and treatment of gallstones. German Society for Digestive and Metabolic Diseases and German Society for Surgery of the Alimentary Tract. Zeitschrift fur Gastroenterologie 2007; 45: 971-1001
• 458 Meacock LM, Sellars ME, Sidhu PS. Evaluation of gallbladder and biliary duct disease using microbubble contrast-enhanced ultrasound. The British journal of radiology 2010; 83: 615-627
• 459 Tsuji S, Sofuni A, Moriyasu F. et al. Contrast-enhanced ultrasonography in the diagnosis of gallbladder disease. Hepatogastroenterology 2012; 59: 336-340
• 460 Sugiyama M, Atomi Y, Yamato T. Endoscopic ultrasonography for differential diagnosis of polypoid gall bladder lesions: analysis in surgical and follow up series. Gut 2000; 46: 250-254
• 461 Muguruma N, Okamura S, Ichikawa S. et al. Endoscopic sonography in the diagnosis of gallbladder wall lesions in patients with gallstones. Journal of clinical ultrasound: JCU 2001; 29: 395-400
• 462 Lutz HH, Wasmuth HE, Streetz K. et al. Endoscopic ultrasound as an early diagnostic tool for primary sclerosing cholangitis: a prospective pilot study. Endoscopy 2012; 44: 934-939
• 463 Nguyen NQ, Schoeman MN, Ruszkiewicz A. Clinical utility of EUS before cholangioscopy in the evaluation of difficult biliary strictures. Gastrointestinal endoscopy 2013; 78: 868-874
• 464 Kubota K, Kato S, Uchiyama T. et al. Discrimination between sclerosing cholangitis-associated autoimmune pancreatitis and primary sclerosing cholangitis, cancer using intraductal ultrasonography. Digestive endoscopy: official journal of the Japan Gastroenterological Endoscopy Society 2011; 23: 10-16
• 465 Naitoh I, Nakazawa T, Hayashi K. et al. Comparison of intraductal ultrasonography findings between primary sclerosing cholangitis and IgG4-related sclerosing cholangitis. Journal of gastroenterology and hepatology 2015; 30: 1104-1109
• 466 Hirschfield GM, Karlsen TH, Lindor KD. et al. Primary sclerosing cholangitis. Lancet 2013; 382: 1587-1599
• 467 Tsaitas C, Semertzidou A, Sinakos E. Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. World journal of hepatology 2014; 6: 178-187
• 468 Lindor KD, Kowdley KV, Harrison ME. ACG Clinical Guideline: Primary Sclerosing Cholangitis. The American journal of gastroenterology 2015; 110: 646-659 ; quiz 60
• 469 Jorgensen RA, Lindor KD, Sartin JS. et al. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol 1995; 20: 215-219
• 470 Angulo P, Grandison GA, Fong DG. et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 2011; 140: 180-188
• 471 Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. The New England journal of medicine 1997; 336: 691-695
• 472 Lindor KD, Kowdley KV, Luketic VA. et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-814
• 473 Olsson R, Boberg KM, de Muckadell OS. et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129: 1464-1472
• 474 Triantos CK, Koukias NM, Nikolopoulou VN. et al. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther 2011; 34: 901-910
• 475 Al Mamari S, Djordjevic J, Halliday JS. et al. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2013; 58: 329-334
• 476 Stanich PP, Bjornsson E, Gossard AA. et al. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2011; 43: 309-313
• 477 Wunsch E, Trottier J, Milkiewicz M. et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology 2014; 60: 931-940
• 478 Cullen SN, Rust C, Fleming K. et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008; 48: 792-800
• 479 Harnois DM, Angulo P, Jorgensen RA. et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. The American journal of gastroenterology 2001; 96: 1558-1562
• 480 Fickert P, Zollner G, Fuchsbichler A. et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002; 123: 1238-1251
• 481 Imam MH, Sinakos E, Gossard AA. et al. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther 34: 1185-1192
• 482 Eaton JE, Silveira MG, Pardi DS. et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. The American journal of gastroenterology 2011; 106: 1638-1645
• 483 Sinakos E, Marschall HU, Kowdley KV. et al. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. Hepatology 2010; 52: 197-203
• 484 Fickert P, Fuchsbichler A, Marschall HU. et al. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol 2006; 168: 410-422
• 485 Chapman R, Fevery J, Kalloo A. et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-678
• 486 Dignass A, Preiss JC, Aust DE. et al. Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011. Zeitschrift fur Gastroenterologie 2011; 49: 1276-1341
• 487 Preiss JC, Bokemeyer B, Buhr HJ. et al. Updated German clinical practice guideline on "Diagnosis and treatment of Crohn's disease" 2014. Zeitschrift fur Gastroenterologie 2014; 52: 1431-1484
• 488 Van Assche G, Dignass A, Bokemeyer B. et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013; 7: 1-33
• 489 Van Assche G, Dignass A, Reinisch W. et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis 2010; 4: 63-101
• 490 Hansen JD, Kumar S, Lo WK. et al. Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis. Digestive diseases and sciences 2013; 58: 3079-3087
• 491 Tung BY, Emond MJ, Haggitt RC. et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134: 89-95
• 492 Pardi DS, Loftus Jr EV, Kremers WK. et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-893
• 493 Brandsaeter B, Isoniemi H, Broome U. et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004; 40: 815-822
• 494 Schramm C, Schirmacher P, Helmreich-Becker I. et al. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann Intern Med 1999; 131: 943-946
• 495 Boberg KM, Egeland T, Schrumpf E. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand J Gastroenterol 2003; 38: 991-995
• 496 Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994; 106: 494-499
• 497 Talwalkar JA, Angulo P, Keach JC. et al. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. The American journal of gastroenterology 2005; 100: 308-312
• 498 Talwalkar JA, Gossard AA, Keach JC. et al. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver international: official journal of the International Association for the Study of the Liver 2007; 27: 451-453
• 499 Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Digestive diseases and sciences 2004; 49: 1-4
• 500 Hommes DW, Erkelens W, Ponsioen C. et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol 2008; 42: 522-526
• 501 Davies YK, Cox KM, Abdullah BA. et al. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 2008; 47: 61-67
• 502 Tabibian JH, Weeding E, Jorgensen RA. et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis – a pilot study. Aliment Pharmacol Ther 2013; 37: 604-612
• 503 Farkkila M, Karvonen AL, Nurmi H. et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004; 40: 1379-1386
• 504 Tabibian JH, Gossard A, El-Youssef M. et al. Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis. Am J Ther 2017; 24: e56-e63
• 505 Andersen IM, Tengesdal G, Lie BA. et al. Effects of coffee consumption, smoking, and hormones on risk for primary sclerosing cholangitis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 12: 1019-1028
• 506 Lammert C, Juran BD, Schlicht E. et al. Reduced coffee consumption among individuals with primary sclerosing cholangitis but not primary biliary cirrhosis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2014; 12: 1562-1568
• 507 Martin CR, Blanco PG, Keach JC. et al. The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis – a pilot study. Aliment Pharmacol Ther 2012; 35: 255-265
• 508 Angulo P, Jorgensen RA, Kowdley KV. et al. Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Digestive diseases and sciences 2008; 53: 1716-1720
• 509 Gotthardt DN, Rudolph G, Kloters-Plachky P. et al. Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment. Gastrointestinal endoscopy 2010; 71: 527-534
• 510 Siddiqui UD, Banerjee S, Barth B. et al. Tools for endoscopic stricture dilation. Gastrointestinal endoscopy 2013; 78: 391-404
• 511 Faigel DO, Ginsberg GG, Kochman ML. Innovative use of the Soehendra stent retriever for biliary stricture recannalization. Gastrointestinal endoscopy 1996; 44: 635
• 512 Kaya M, Petersen BT, Angulo P. et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. The American journal of gastroenterology 2001; 96: 1059-1066
• 513 van Milligen de Wit AW, Rauws EA, van Bracht J. et al. Lack of complications following short-term stent therapy for extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointestinal endoscopy 1997; 46: 344-347
• 514 Baluyut AR, Sherman S, Lehman GA. et al. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointestinal endoscopy 2001; 53: 308-312
• 515 Gluck M, Cantone NR, Brandabur JJ. et al. A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis. J Clin Gastroenterol 2008; 42: 1032-1039
• 516 Stiehl A, Rudolph G, Kloters-Plachky P. et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002; 36: 151-156
• 517 Martin JA. Endoscopic Management of Primary Sclerosing Cholangitis: State of the Art. The American journal of gastroenterology 2007; 102: S32-S37
• 518 Olsson R, Bjornsson E, Backman L. et al. Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. J Hepatol 1998; 28: 426-432
• 519 Kaya M, Bestas R, Bacalan F. et al. Microbial profile and antibiotic sensitivity pattern in bile cultures from endoscopic retrograde cholangiography patients. World journal of gastroenterology 2012; 18: 3585-3589
• 520 Negm AA, Schott A, Vonberg RP. et al. Routine bile collection for microbiological analysis during cholangiography and its impact on the management of cholangitis. Gastrointestinal endoscopy 2010; 72: 284-291
• 521 Pohl J, Ring A, Stremmel W. et al. The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. European journal of gastroenterology & hepatology 2006; 18: 69-74
• 522 Voigtlander T, Leuchs E, Vonberg RP. et al. Microbiological analysis of bile and its impact in critically ill patients with secondary sclerosing cholangitis. J Infect 2015; 70: 483-490
• 523 Bai Y, Gao F, Gao J. et al. Prophylactic antibiotics cannot prevent endoscopic retrograde cholangiopancreatography-induced cholangitis: a meta-analysis. Pancreas 2009; 38: 126-130
• 524 Harris A, Chan AC, Torres-Viera C. et al. Meta-analysis of antibiotic prophylaxis in endoscopic retrograde cholangiopancreatography (ERCP). Endoscopy 1999; 31: 718-724
• 525 Brand M, Bizos D, O'Farrell Jr P. Antibiotic prophylaxis for patients undergoing elective endoscopic retrograde cholangiopancreatography. Cochrane Database Syst Rev 2010; DOI: CD007345.
• 526 Denzer U, Beilenhoff U, Eickhoff A. et al. S2k guideline: quality requirements for gastrointestinal endoscopy, AWMF registry no. 021–022. Zeitschrift fur Gastroenterologie 2015; 53: 1496-1530
• 527 Alkhatib AA, Hilden K, Adler DG. Comorbidities, sphincterotomy, and balloon dilation predict post-ERCP adverse events in PSC patients: operator experience is protective. Digestive diseases and sciences 2011; 56: 3685-3688
• 528 Etzel JP, Eng SC, Ko CW. et al. Complications after ERCP in patients with primary sclerosing cholangitis. Gastrointestinal endoscopy 2008; 67: 643-648
• 529 Ismail S, Kylanpaa L, Mustonen H. et al. Risk factors for complications of ERCP in primary sclerosing cholangitis. Endoscopy 2012; 44: 1133-1138
• 530 Navaneethan U, Jegadeesan R, Nayak S. et al. ERCP-related adverse events in patients with primary sclerosing cholangitis. Gastrointestinal endoscopy 2015; 81: 410-419
• 531 van den Hazel SJ, Wolfhagen EH, van Buuren HR. et al. Prospective risk assessment of endoscopic retrograde cholangiography in patients with primary sclerosing cholangitis. Dutch PSC Study Group. Endoscopy 2000; 32: 779-782
• 532 Bangarulingam SY, Gossard AA, Petersen BT. et al. Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. The American journal of gastroenterology 2009; 104: 855-860
• 533 Broome U, Lofberg R, Veress B. et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22: 1404-1408
• 534 Torres J, Pineton de Chambrun G, Itzkowitz S. et al. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther 34: 497-508
• 535 Lian L, Menon KV, Shen B. et al. Inflammatory bowel disease complicated by primary sclerosing cholangitis and cirrhosis: is restorative proctocolectomy safe?. Dis Colon Rectum 2012; 55: 79-84
• 536 Kartheuser AH, Dozois RR, LaRusso NF. et al. Comparison of surgical treatment of ulcerative colitis associated with primary sclerosing cholangitis: ileal pouch-anal anastomosis versus Brooke ileostomy. Mayo Clin Proc 1996; 71: 748-756
• 537 Wiesner RH, LaRusso NF, Dozois RR. et al. Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis. Gastroenterology 1986; 90: 316-322
• 538 Penna C, Dozois R, Tremaine W. et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996; 38: 234-239
• 539 Gorgun E, Remzi FH, Manilich E. et al. Surgical outcome in patients with primary sclerosing cholangitis undergoing ileal pouch-anal anastomosis: a case-control study. Surgery 2005; 138: 631-637 ; discussion 7–9
• 540 Cairns SR, Scholefield JH, Steele RJ. et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010; 59: 666-689
• 541 Imam MH, Eaton JE, Puckett JS. et al. Neoplasia in the ileoanal pouch following colectomy in patients with ulcerative colitis and primary sclerosing cholangitis. J Crohns Colitis 2014; 8: 1294-1299
• 542 Ludvigsson JF, Bergquist A, Ajne G. et al. A population-based cohort study of pregnancy outcomes among women with primary sclerosing cholangitis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2014; 12: 95-100 e1
• 543 Vesterhus M, Hov JR, Holm A. et al. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology 2015; 62: 188-197
• 544 Mendes FD, Jorgensen R, Keach J. et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. The American journal of gastroenterology 2006; 101: 2070-2075
• 545 Kim WR, Therneau TM, Wiesner RH. et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000; 75: 688-694
• 546 Rupp C, Bode KA, Chahoud F. et al. Risk factors and outcome in patients with primary sclerosing cholangitis with persistent biliary candidiasis. BMC Infect Dis 2014; 14: 562
• 547 Venkatesh PG, Navaneethan U, Shen B. et al. Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Digestive diseases and sciences 2013; 58: 850-857
• 548 Kim WR, Poterucha JJ, Wiesner RH. et al. The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology 1999; 29: 1643-1648
• 549 Ponsioen CY, Vrouenraets SM, Prawirodirdjo W. et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002; 51: 562-566
• 550 Ponsioen CY, Reitsma JB, Boberg KM. et al. Validation of a cholangiographic prognostic model in primary sclerosing cholangitis. Endoscopy 2010; 42: 742-747
• 551 Craig DA, MacCarty RL, Wiesner RH. et al. Primary sclerosing cholangitis: value of cholangiography in determining the prognosis. Am JRoentgenol American journal of roentgenology 1991; 157: 959-964
• 552 Rajaram R, Ponsioen CY, Majoie CB. et al. Evaluation of a modified cholangiographic classification system for primary sclerosing cholangitis. Abdom Imaging 2001; 26: 43-47
• 553 Friedrich K, Rupp C, Hov JR. et al. A frequent PNPLA3 variant is a sex specific disease modifier in PSC patients with bile duct stenosis. PloS one 2013; 8: e58734
• 554 Rudolph G, Gotthardt D, Kloeters-Plachky P. et al. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol 2010; 53: 313-317
• 555 Rudolph G, Gotthardt D, Kloters-Plachky P. et al. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol 2009; 51: 149-155
• 556 Korkmaz KS, de Rooij BJ, van Hoek B. et al. MMP-2 is a disease-modifying gene in primary sclerosing cholangitis. Liver international: official journal of the International Association for the Study of the Liver 2014; 34: 274-280
• 557 Melum E, Karlsen TH, Bergquist A. et al. An interleukin-6 (IL-6) receptor polymorphism affecting serum levels of IL-6 does not increase the risk of cholangiocarcinoma in primary sclerosing cholangitis. The American journal of gastroenterology 2008; 103: 1045 ; author reply 6
• 558 Rupp C, Mummelthei A, Sauer P. et al. Non-IBD immunological diseases are a risk factor for reduced survival in PSC. Liver international: official journal of the International Association for the Study of the Liver 2013; 33: 86-93
• 559 Karlsen TH, Lie BA, Frey Froslie K. et al. Polymorphisms in the steroid and xenobiotic receptor gene influence survival in primary sclerosing cholangitis. Gastroenterology 2006; 131: 781-787
• 560 Shetty K, Rybicki L, Carey WD. The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatology 1997; 25: 1049-1053
• 561 Eaton JE, Dzyubak B, Venkatesh SK. et al. Performance of magnetic resonance elastography in primary sclerosing cholangitis. Journal of gastroenterology and hepatology 2016; 31: 1184-1190
• 562 Hinrichs H, Hinrichs JB, Gutberlet M. et al. Functional gadoxetate disodium-enhanced MRI in patients with primary sclerosing cholangitis (PSC). European radiology 2016; 26: 1116-1124
• 563 Kim JH, Byun JH, Kim SY. et al. Sclerosing cholangitis with autoimmune pancreatitis versus primary sclerosing cholangitis: comparison on endoscopic retrograde cholangiography, MR cholangiography, CT, and MRI. Acta radiologica 2013; 54: 601-607
• 564 Nilsson H, Blomqvist L, Douglas L. et al. Dynamic gadoxetate-enhanced MRI for the assessment of total and segmental liver function and volume in primary sclerosing cholangitis. Journal of magnetic resonance imaging: JMRI 2014; 39: 879-886
• 565 Tokala A, Khalili K, Menezes R. et al. Comparative MRI analysis of morphologic patterns of bile duct disease in IgG4-related systemic disease versus primary sclerosing cholangitis. Am J Roentgenol American journal of roentgenology 2014; 202: 536-543
• 566 Zein CO, Lindor KD, Angulo P. Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology 2004; 39: 204-210
• 567 Bergquist A, Ekbom A, Olsson R. et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36: 321-327
• 568 Burak K, Angulo P, Pasha TM. et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. The American journal of gastroenterology 2004; 99: 523-526
• 569 Zenouzi R, Weismuller TJ, Hubener P. et al. Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2014; 12: 1733-1738
• 570 Harnois DM, Gores GJ, Ludwig J. et al. Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer?. J Hepatol 1997; 27: 512-516
• 571 de Valle MB, Bjornsson E, Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver international: official journal of the International Association for the Study of the Liver 2012; 32: 441-448
• 572 Lee YM, Kaplan MM. Primary sclerosing cholangitis. The New England journal of medicine 1995; 332: 924-933
• 573 Rosen CB, Nagorney DM, Wiesner RH. et al. Cholangiocarcinoma complicating primary sclerosing cholangitis. Annals of surgery 1991; 213: 21-25
• 574 Wildner D, Bernatik T, Greis C. et al. CEUS in Hepatocellular Carcinoma and Intrahepatic Cholangiocellular Carcinoma in 320 Patients – Early or Late Washout Matters: A Subanalysis of the DEGUM Multicenter Trial. Ultraschall in Med 2015; 36: 132-139
• 575 Ehlken H, Wroblewski R, Corpechot C. et al. Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis. Gut 2016; 65: 1230-1232
• 576 Corpechot C, El Naggar A, Poujol-Robert A. et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006; 43: 1118-1124
• 577 Ehlken H, Lohse AW, Schramm C. Transient elastography in primary sclerosing cholangitis-the value as a prognostic factor and limitations. Gastroenterology 147: 542-543
• 578 Bangarulingam SY, Bjornsson E, Enders F. et al. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology 2010; 51: 174-180
• 579 Lankisch TO, Metzger J, Negm AA. et al. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology 53: 875-884
• 580 Hultcrantz R, Olsson R, Danielsson A. et al. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 1999; 30: 669-673
• 581 Wannhoff A, Hov JR, Folseraas T. et al. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 2013; 59: 1278-1284
• 582 Levy C, Lymp J, Angulo P. et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Digestive diseases and sciences 2005; 50: 1734-1740
• 583 Sinakos E, Saenger AK, Keach J. et al. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2011; 9: 434-439 e1
• 584 Wannhoff A, Rupp C, Friedrich K. et al. Inflammation But Not Biliary Obstruction Is Associated With Carbohydrate Antigen 19-9 Levels in Patients With Primary Sclerosing Cholangitis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2015; 13: 2372-2379
• 585 Ramage JK, Donaghy A, Farrant JM. et al. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995; 108: 865-869
• 586 Siqueira E, Schoen RE, Silverman W. et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointestinal endoscopy 2002; 56: 40-47
• 587 Wannhoff A, Folseraas T, Brune M. et al. A common genetic variant of fucosyltransferase 2 correlates with serum carcinoembryonic antigen levels and affects cancer screening in patients with primary sclerosing cholangitis. United European Gastroenterology Journal 2016; 4: 84-91
• 588 Lindberg B, Arnelo U, Bergquist A. et al. Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis. Endoscopy 2002; 34: 909-916
• 589 Lewis JT, Talwalkar JA, Rosen CB. et al. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. The American journal of surgical pathology 2007; 31: 907-913
• 590 Schulze K, Weismuller TJ, Bubenheim M. et al. Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with Primary Sclerosing Cholangitis. PloS one 2015; 10: e0140525
• 591 Mieli-Vergani G, Vergani D. Autoimmune hepatitis in children: what is different from adult AIH?. Seminars in liver disease 2009; 29: 297-306
• 592 Pando M, Larriba J, Fernandez GC. et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999; 30: 1374-1380
• 593 Woynarowski M, Woźniak M, Pawłowska M. et al. Autoimmune hepatitis in Polish children: Healthcare facilities, epidemiology, and standards of care assessed by a pediatric autoimmune hepatitis group. E&C Hepatology 2008; 4: 66-70
• 594 Deneau M, Jensen MK, Holmen J. et al. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology 2013; 58: 1392-1400
• 595 Oettinger R, Brunnberg A, Gerner P. et al. Clinical features and biochemical data of Caucasian children at diagnosis of autoimmune hepatitis. J Autoimmun 2005; 24: 79-84
• 596 Di Giorgio A, Bravi M, Bonanomi E. et al. Fulminant hepatic failure of autoimmune aetiology in children. J Pediatr Gastroenterol Nutr 2015; 60: 159-164
• 597 Mieli-Vergani G, Vergani D. Autoimmune hepatitis. Nat Rev Gastroenterol Hepatol 2011; 8: 320-329
• 598 Radhakrishnan KR, Alkhouri N, Worley S. et al. Autoimmune hepatitis in children--impact of cirrhosis at presentation on natural history and long-term outcome. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010; 42: 724-728
• 599 Martin SR, Alvarez F, Anand R. et al. Outcomes in children who underwent transplantation for autoimmune hepatitis. Liver Transpl 2011; 17: 393-401
• 600 Vergani D, Wells L, Larcher VF. et al. Genetically determined low C4: a predisposing factor to autoimmune chronic active hepatitis. Lancet 1985; 2: 294-298
• 601 Della Corte C, Ranucci G, Tufano M. et al. Autoimmune hepatitis type 2 arising in PFAPA syndrome: coincidences or possible correlations?. Pediatrics 2010; 125: e683-e686
• 602 Tufano M, Della Corte C, Cirillo F. et al. Fulminant autoimmune hepatitis in a girl with 22q13 deletion syndrome: a previously unreported association. Eur J Pediatr 2009; 168: 225-227
• 603 Lopez SI, Ciocca M, Oleastro M. et al. Autoimmune hepatitis type 2 in a child with IPEX syndrome. J Pediatr Gastroenterol Nutr 2011; 53: 690-693
• 604 Mieli-Vergani G, Vergani D. Autoimmune liver diseases in children – what is different from adulthood?. Best Pract Res Clin Gastroenterol 2011; 25: 783-795
• 605 Ma Y, Okamoto M, Thomas MG. et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35: 658-664
• 606 Ebbeson RL, Schreiber RA. Diagnosing autoimmune hepatitis in children: is the International Autoimmune Hepatitis Group scoring system useful?. ClinGastroenterol Hepatol 2004; 2: 935-940
• 607 Mileti E, Rosenthal P, Peters MG. Validation and modification of simplified diagnostic criteria for autoimmune hepatitis in children. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2012; 10: 417-421 e1-2
• 608 Ramakrishna J, Johnson AR, Banner BF. Long-term minocycline use for acne in healthy adolescents can cause severe autoimmune hepatitis. J Clin Gastroenterol 2009; 43: 787-790
• 609 Della Corte C, Sartorelli MR, Sindoni CD. et al. Autoimmune hepatitis in children: an overview of the disease focusing on current therapies. European journal of gastroenterology & hepatology 2012; 24: 739-746
• 610 Mieli-Vergani G, Heller S, Jara P. et al. Autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2009; 49: 158-164
• 611 Samaroo B, Samyn M, Buchanan C. et al. Longterm daily oral treatment with predisolone in children with autoimmune liver disease does not affect final adult height. Hepatology 2006; 44: 438A
• 612 Woynarowski M, Nemeth A, Baruch Y. et al. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. JPediatr 2013; 163: 1347-1353
• 613 Nguyen TM, Daubard M, Le Gall C. et al. Monitoring of azathioprine metabolites in pediatric patients with autoimmune hepatitis. Ther Drug Monit 2010; 32: 433-437
• 614 Aw MM, Dhawan A, Samyn M. et al. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009; 51: 156-160
• 615 Cuarterolo M, Ciocca M, Velasco CC. et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 2006; 43: 635-639
• 616 D'Agostino D, Costaguta A, Alvarez F. Successful treatment of refractory autoimmune hepatitis with rituximab. Pediatrics 2013; 132: e526-e530
• 617 Kerkar N, Miloh T. Sclerosing cholangitis: pediatric perspective. Current gastroenterology reports 2010; 12: 195-202
• 618 Girard M, Franchi-Abella S, Lacaille F. et al. Specificities of sclerosing cholangitis in childhood. Clin Res Hepatol Gastroenterol 2012; 36: 530-535
• 619 Debray D, Pariente D, Urvoas E. et al. Sclerosing cholangitis in children. J Pediatr 1994; 124: 49-56
• 620 Wilschanski M, Chait P, Wade JA. et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology 1995; 22: 1415-1422
• 621 Batres LA, Russo P, Mathews M. et al. Primary sclerosing cholangitis in children: a histologic follow-up study. Pediatr Dev Pathol 2005; 8: 568-576
• 622 Miloh T, Arnon R, Shneider B. et al. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol 2009; 7: 239-245
• 623 Mieli-Vergani G, Vergani D. Sclerosing cholangitis in the paediatric patient. Best Pract Res Clin Gastroenterol 2001; 15: 681-690
• 624 Feldstein AE, Perrault J, El-Youssif M. et al. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 2003; 38: 210-217
• 625 Feldmeyer L, Huber M, Fellmann F. et al. Confirmation of the origin of NISCH syndrome. Hum Mutat 2006; 27: 408-410
• 626 Mieli-Vergani G, Vergani D. Autoimmune paediatric liver disease 1. World J Gastroenterol 2008; 14: 3360-3367
• 627 Al-Saud BK, Al-Sum Z, Alassiri H. et al. Clinical, immunological, and molecular characterization of hyper-IgM syndrome due to CD40 deficiency in eleven patients. Journal of clinical immunology 2013; 33: 1325-1335
• 628 Mahdavinia M, Mirsaeidi M, Bishehsari F. et al. Primary sclerosing cholangitis in common variable immune deficiency. Allergol Int 2015; 64: 187-189
• 629 Timmer A, Behrens R, Buderus S. et al. Childhood onset inflammatory bowel disease: predictors of delayed diagnosis from the CEDATA German-language pediatric inflammatory bowel disease registry. J Pediatr 2011; 158: 467-473 e2
• 630 Roberts EA. Primary sclerosing cholangitis in children. Journal of gastroenterology and hepatology 1999; 14: 588-593
• 631 Ibrahim SH, Zhang L, Freese DK. A 3-year-old with immunoglobulin G4-associated cholangitis. J Pediatr Gastroenterol Nutr 2011; 53: 109-111
• 632 Liu JZ, Hov JR, Folseraas T. et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 2013; 45: 670-675
• 633 Liaskou E, Hirschfield GM. Genetic Distinctions in Patients With Primary Sclerosing Cholangitis: Immunoglobulin G4 Elevations and HLA Risk. Gastroenterology 2015; 148: 886-889
• 634 Gulati R, Radhakrishnan KR, Hupertz V. et al. Health-related quality of life in children with autoimmune liver disease. J Pediatr Gastroenterol Nutr 2013; 57: 444-450
• 635 Koh KJ, Lin LH, Huang SH. et al. CARE--pediatric colon adenocarcinoma: a case report and literature review comparing differences in clinical features between children and adult patients. Medicine 2015; 94: e503
• 636 Singer G, Hoellwarth ME. Colorectal carcinomas in children: an institutional experience. Pediatr Surg Int 2012; 28: 591-595
• 637 Amedee-Manesme O, Bernard O, Brunelle F. et al. Sclerosing cholangitis with neonatal onset. J Pediatr 1987; 111: 225-229
• 638 Sisto A, Feldman P, Garel L. et al. Primary sclerosing cholangitis in children: study of five cases and review of the literature. Pediatrics 1987; 80: 918-923
• 639 Maggiore G, Veber F, Bernard O. et al. Autoimmune hepatitis associated with anti-actin antibodies in children and adolescents. Journal of Pediatric Gastroenterology and Nutrition 1993; 17: 376-381
• 640 Campsen J, Zimmerman MA, Trotter JF. et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl 2008; 14: 181-185
• 641 Koukoulis G, Mieli-Vergani G, Portmann B. Infantile liver giant cells: immunohistological study of their proliferative state and possible mechanisms of formation. Pediatr Dev Pathol 1999; 2: 353-359
• 642 Rovelli A, Corti P, Beretta C. et al. Alemtuzumab for giant cell hepatitis with autoimmune hemolytic anemia. J Pediatr Gastroenterol Nutr 2007; 45: 596-599
• 643 Gorelik M, Debski R, Frangoul H. Autoimmune hemolytic anemia with giant cell hepatitis: case report and review of the literature. Journal of pediatric hematology/oncology 2004; 26: 837-839
• 644 Kuntzen T, Friedrichs N, Fischer HP. et al. Postinfantile giant cell hepatitis with autoimmune features following a human herpesvirus 6-induced adverse drug reaction. European journal of gastroenterology & hepatology 2005; 17: 1131-1134
• 645 Bihari C, Rastogi A, Sarin SK. Postinfantile giant cell hepatitis: an etiological and prognostic perspective. Hepatitis research and treatment 2013; 2013: 601290
• 646 Bernard O, Hadchouel M, Scotto J. et al. Severe giant cell hepatitis with autoimmune hemolytic anemia in early childhood. J Pediatr 1981; 99: 704-711
• 647 Raj S, Stephen T, Debski RF. Giant cell hepatitis with autoimmune hemolytic anemia: a case report and review of pediatric literature. Clinical pediatrics 2011; 50: 357-359
• 648 Whitington PF, Vos MB, Bass LM. et al. Humoral immune mechanism of liver injury in giant cell hepatitis with autoimmune hemolytic anemia. J Pediatr Gastroenterol Nutr 2014; 58: 74-80
• 649 Maggiore G, Sciveres M, Fabre M. et al. Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children. J Pediatr 2011; 159: 127-132 e1
• 650 Tajiri K, Shimizu Y, Tokimitsu Y. et al. An elderly man with syncytial giant cell hepatitis successfully treated by immunosuppressants. Internal medicine 2012; 51: 2141-2144
• 651 Thaler H. Post-infantile giant cell hepatitis. Liver 1982; 2: 393-403
• 652 Lau JY, Koukoulis G, Mieli-Vergani G. et al. Syncytial giant-cell hepatitis – a specific disease entity?. J Hepatol 1992; 15: 216-219
• 653 Devaney K, Goodman ZD, Ishak KG. Postinfantile giant-cell transformation in hepatitis. Hepatology 1992; 16: 327-333
• 654 Shores D, Kobak G, Pegram LD. et al. Giant cell hepatitis and immune thrombocytopenic purpura: reversal of liver failure with rituximab therapy. J Pediatr Gastroenterol Nutr 2012; 55: e128-e130
• 655 Melendez HV, Rela M, Baker AJ. et al. Liver transplant for giant cell hepatitis with autoimmune haemolytic anaemia. Arch Dis Child 1997; 77: 249-251
• 656 Brichard B, Sokal E, Gosseye S. et al. Coombs-positive giant cell hepatitis of infancy: effect of steroids and azathioprine therapy. Eur J Pediatr 1991; 150: 314-317
• 657 Paganelli M, Patey N, Bass LM. et al. Anti-CD20 treatment of giant cell hepatitis with autoimmune hemolytic anemia. Pediatrics 2014; 134: e1206-e1210
• 658 Bakula A, Socha P, Klaudel-Dreszler M. et al. Giant cell hepatitis with autoimmune hemolytic anemia in children: proposal for therapeutic approach. J Pediatr Gastroenterol Nutr 2014; 58: 669-673
• 659 Lega S, Maschio M, Taddio A. et al. Giant cell hepatitis with Coombs-positive haemolytic anaemia: steroid sparing with high-dose intravenous immunoglobulin and cyclosporine. Acta paediatrica 2013; 102: e137-e139
• 660 Bouguila J, Mabrouk S, Tilouche S. et al. Giant cell hepatitis with autoimmune hemolytic anemia in a nine month old infant. World journal of hepatology 2013; 5: 226-229
• 661 Miloh T, Manwani D, Morotti R. et al. Giant cell hepatitis and autoimmune hemolytic anemia successfully treated with rituximab. J Pediatr Gastroenterol Nutr 2007; 44: 634-636
• 662 Eroglu Y, Duzovali O, Kavukcu S. et al. Combination of steroid with azathioprine in treatment of giant cell autoimmune hepatitis. The Turkish journal of pediatrics 1997; 39: 565-571
• 663 Weinstein T, Valderrama E, Pettei M. et al. Early steroid therapy for the treatment of giant cell hepatitis with autoimmune hemolytic anemia. J Pediatr Gastroenterol Nutr 1993; 17: 313-316
• 664 Vajro P, Migliaro F, Ruggeri C. et al. Life saving cyclophosphamide treatment in a girl with giant cell hepatitis and autoimmune haemolytic anaemia: case report and up-to-date on therapeutical options. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2006; 38: 846-850
• 665 Pappo O, Yunis E, Jordan JA. et al. Recurrent and de novo giant cell hepatitis after orthotopic liver transplantation. The American journal of surgical pathology 1994; 18: 804-813
• 666 Durand F, Degott C, Sauvanet A. et al. Subfulminant syncytial giant cell hepatitis: recurrence after liver transplantation treated with ribavirin. J Hepatol 1997; 26: 722-726
• 667 Lerut JP, Claeys N, Ciccarelli O. et al. Recurrent postinfantile syncytial giant cell hepatitis after orthotopic liver transplantation. Transpl Int 1998; 11: 320-322
• 668 Cholongitas E, Shusang V, Papatheodoridis GV. et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008; 14: 138-143
• 669 Alabraba E, Nightingale P, Gunson B. et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009; 15: 330-340
• 670 Carbone M, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol 2014; 60: 210-223
• 671 Bergquist A, Lindberg G, Saarinen S. et al. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol 2005; 42: 252-256
• 672 Graziadei IW. Live donor liver transplantation for primary sclerosing cholangitis: is disease recurrence increased?. Curr Opin Gastroenterol 2011; 27: 301-305
• 673 Mottershead M, Neuberger J. Transplantation in autoimmune liver diseases. World journal of gastroenterology 2008; 14: 3388-3395
• 674 Tamura S, Sugawara Y, Kaneko J. et al. Recurrence of primary sclerosing cholangitis after living donor liver transplantation. Liver international: official journal of the International Association for the Study of the Liver 2007; 27: 86-94
• 675 Egawa H, Ueda Y, Ichida T. et al. Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation in Japanese registry. Am J Transplant 2011; 11: 518-527
• 676 Gruttadauria S, Marsh JW, Vizzini GB. et al. Analysis of surgical and perioperative complications in seventy-five right hepatectomies for living donor liver transplantation. World journal of gastroenterology 2008; 14: 3159-3164
• 677 Abecassis MM, Fisher RA, Olthoff KM. et al. Complications of living donor hepatic lobectomy--a comprehensive report. Am J Transplant 2012; 12: 1208-1217
• 678 Ladner DP, Dew MA, Forney S. et al. Long-term quality of life after liver donation in the adult to adult living donor liver transplantation cohort study (A2ALL). J Hepatol 2015; 62: 346-353
• 679 Hasegawa Y, Kawachi S, Shimazu M. et al. Discontinuation of living donor liver transplantation for PSC due to histological abnormalities in intraoperative donor liver biopsy. Am J Transplant 2007; 7: 2204-2207
• 680 Merion RM, Schaubel DE, Dykstra DM. et al. The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307-313
• 681 Potts JR, Verma S. Optimizing management in autoimmune hepatitis with liver failure at initial presentation. World journal of gastroenterology 2011; 17: 2070-2075
• 682 Verma S, Maheshwari A, Thuluvath P. Liver failure as initial presentation of autoimmune hepatitis: clinical characteristics, predictors of response to steroid therapy, and outcomes. Hepatology 2009; 49: 1396-1397
• 683 Ichai P, Duclos-Vallee JC, Guettier C. et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007; 13: 996-1003
• 684 Transplantationsgesetz. Gesetz über die Spende, Entnahme und Übertragung von Organen und Geweben (Transplantationsgesetz – TPG). https://wwwgesetze-im-internetde/tpg/BJNR263100997html
• 685 Bundesärztekammer R. Transplantationsmedizin; Richtlinien für die Wartelistenführung und die Organvermittlung. http://wwwbundesaerztekammerde/richtlinien/richtlinien/transplantationsmedizin/richtlinien-fuer-die-wartelistenfuehrung-und-die-organvermittlung/
• 686 Schramm C, Bubenheim M, Adam R. et al. Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. Liver Transpl 2010; 16: 461-469
• 687 Gelson W, Hoare M, Dawwas MF. et al. The pattern of late mortality in liver transplant recipients in the United Kingdom. Transplantation 2011; 91: 1240-1244
• 688 Futagawa Y, Terasaki PI. An analysis of the OPTN/UNOS Liver Transplant Registry. Clin Transpl 2004; 315-329
• 689 Futagawa Y, Terasaki PI, Waki K. et al. No improvement in long-term liver transplant graft survival in the last decade: an analysis of the UNOS data. Am J Transplant 2006; 6: 1398-1406
• 690 Kashyap R, Safadjou S, Chen R. et al. Living donor and deceased donor liver transplantation for autoimmune and cholestatic liver diseases--an analysis of the UNOS database. J Gastrointest Surg 2010; 14: 1362-1369
• 691 Escorsell A, Mas A, de la Mata M. et al. Acute liver failure in Spain: analysis of 267 cases. Liver Transpl 2007; 13: 1389-1395
• 692 Brandsaeter B, Hockerstedt K, Friman S. et al. Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation-12 years experience in the nordic countries. Liver Transpl 2002; 8: 1055-1062
• 693 Lee WM, Squires Jr RH, Nyberg SL. et al. Acute liver failure: Summary of a workshop. Hepatology 2008; 47: 1401-1415
• 694 Ahmed M, Mutimer D, Hathaway M. et al. Liver transplantation for autoimmune hepatitis: a 12-year experience. Transplantation proceedings 1997; 29: 496
• 695 Vogel A, Heinrich E, Bahr MJ. et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 2004; 18: 62-69
• 696 Strassburg CP, Manns MP. Therapy of autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2011; 25: 673-687
• 697 Rowe IA, Webb K, Gunson BK. et al. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008; 21: 459-465
• 698 Beckebaum S, Iacob S, Klein CG. et al. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients. Transplantation 2010; 89: 983-993
• 699 Wildner D, Strobel D, Konturek PC. et al. Impact of acoustic radiation force impulse imaging in clinical practice of patients after orthotopic liver transplantation. Med Sci Monit 2014; 20: 2027-2035
• 700 Osteologie DV. Leitlinien Osteoporose. 2014 http://wwwdv-osteologieorg/dvo_leitlinien/osteoporose-leitlinie-2014
• 701 Lucey MR, Terrault N, Ojo L. et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013; 19: 3-26
• 702 Molmenti EP, Netto GJ, Murray NG. et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl 2002; 8: 519-526
• 703 Campsen J, Zimmerman MA, Trotter JF. et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl 2008; 14: 1281-1286
• 704 Gonzalez-Koch A, Czaja AJ, Carpenter HA. et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001; 7: 302-310
• 705 Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006; 12: 1813-1824
• 706 Beckebaum S, Cicinnati VR, Broelsch CE. et al. Recurrent disease after liver transplantation. A therapeutic dilemma or treatable?. Med Klin (Munich) 2006; 101: 939-950
• 707 Banff Working G, Demetris AJ, Adeyi O. et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006; 44: 489-501
• 708 Czaja AJ. Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. Digestive diseases and sciences 2012; 57: 2248-2266
• 709 Wright HL, Bou-Abboud CF, Hassanein T. et al. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease. Transplantation 1992; 53: 136-139
• 710 Sempoux C, Horsmans Y, Lerut J. et al. Acute lobular hepatitis as the first manifestation of recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver 1997; 17: 311-315
• 711 Czaja AJ. The immunoreactive propensity of autoimmune hepatitis: is It corticosteroid-dependent after liver transplantation?. Liver transplantation and surgery: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 1999; 5: 460-463
• 712 Montano-Loza AJ, Mason AL, Ma M. et al. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl 2009; 15: 1254-1261
• 713 Gotz G, Neuhaus R, Bechstein WO. et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation proceedings 1999; 31: 430-431
• 714 Vergani D, Mieli-Vergani G. Autoimmunity after liver transplantation. Hepatology 2002; 36: 271-276
• 715 Tripathi D, Neuberger J. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Seminars in liver disease 2009; 29: 286-296
• 716 Jothimani D, Cramp ME, Cross TJ. Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study. J Clin Exp Hepatol 2014; 4: 221-225
• 717 Czaja AJ. Diagnosis and management of autoimmune hepatitis. Clin Liver Dis 2015; 19: 57-79
• 718 Duclos-Vallee JC, Sebagh M. Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation. Liver Transpl 2009; 15 (Suppl. 02) S25-S34
• 719 Trotter JF. Is disease recurrence still relevant to graft survival?. Liver Transpl 2013; 19 (Suppl. 02) S49-S55
• 720 Lohse AW, Weiler-Norman C, Burdelski M. De novo autoimmune hepatitis after liver transplantation. Hepatol Res 2007; 37 (Suppl. 03) S462
• 721 Montano-Loza AJ, Vargas-Vorackova F, Ma M. et al. Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation. Liver international: official journal of the International Association for the Study of the Liver 2012; 32: 1426-1433
• 722 Neil DA, Hubscher SG. Current views on rejection pathology in liver transplantation. Transpl Int 2010; 23: 971-983
• 723 Miyagawa-Hayashino A, Haga H, Egawa H. et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation 2004; 78: 128-135
• 724 Heneghan MA, Portmann BC, Norris SM. et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001; 34: 464-470
• 725 Venick RS, McDiarmid SV, Farmer DG. et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant 2007; 7: 955-963
• 726 Richter A, Grabhorn E, Helmke K. et al. Clinical relevance of autoantibodies after pediatric liver transplantation. Clin Transplant 2007; 21: 427-432
• 727 Duclos-Vallee JC, Johanet C, Bach JF. et al. Autoantibodies associated with acute rejection after liver transplantation for type-2 autoimmune hepatitis. J Hepatol 2000; 33: 163-166
• 728 O'Grady J. The immunoreactive patient: Rejection and autoimmune disease. Liver Transpl 2011; 17 (Suppl. 03) S29-S33
• 729 Hernandez HM, Kovarik P, Whitington PF. et al. Autoimmune hepatitis as a late complication of liver transplantation. J Pediatr Gastroenterol Nutr 2001; 32: 131-136
• 730 Cauch-Dudek K, Abbey S, Stewart DE. et al. Fatigue in primary biliary cirrhosis. Gut 1998; 43: 705-710
• 731 Carbone M, Bufton S, Monaco A. et al. The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study. J Hepatol 2013; 59: 490-494
• 732 European Association for the Study of the L. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267
• 733 Adam R, Karam V, Delvart V. et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012; 57: 675-688
• 734 Adam R, McMaster P, O'Grady JG. et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003; 9: 1231-1243
• 735 Singal AK, Guturu P, Hmoud B. et al. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 2013; 95: 755-760
• 736 Watt KD, Pedersen RA, Kremers WK. et al. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010; 10: 1420-1427
• 737 Barber K, Blackwell J, Collett D. et al. Life expectancy of adult liver allograft recipients in the UK. Gut 2007; 56: 279-282
• 738 Grat M, Lewandowski Z, Patkowski W. et al. Relevance of male-to-female sex mismatch in liver transplantation for primary biliary cirrhosis. Ann Transplant 2015; 20: 116-123
• 739 Montano-Loza AJ, Wasilenko S, Bintner J. et al. Cyclosporine A protects against primary biliary cirrhosis recurrence after liver transplantation. Am J Transplant 2010; 10: 852-858
• 740 Liermann Garcia RF, Evangelista Garcia C, McMaster P. et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001; 33: 22-27
• 741 Silveira MG, Talwalkar JA, Lindor KD. et al. Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant 2010; 10: 720-726
• 742 Shiba H, Wakiyama S, Futagawa Y. et al. Switching from tacrolimus to cyclosporine A to prevent primary biliary cirrhosis recurrence after living-donor liver transplantation. Int Surg 2013; 98: 156-159
• 743 Hashimoto E, Shimada M, Noguchi S. et al. Disease recurrence after living liver transplantation for primary biliary cirrhosis: a clinical and histological follow-up study. Liver Transpl 2001; 7: 588-595
• 744 Khettry U, Anand N, Faul PN. et al. Liver transplantation for primary biliary cirrhosis: a long-term pathologic study. Liver Transpl 2003; 9: 87-96
• 745 Manousou P, Arvaniti V, Tsochatzis E. et al. Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and human leukocyte antigen locus disparity. Liver Transpl 2010; 16: 64-73
• 746 Jacob DA, Neumann UP, Bahra M. et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transplant 2006; 20: 211-220
• 747 Sanchez EQ, Levy MF, Goldstein RM. et al. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation 2003; 76: 1583-1588
• 748 Campsen J, Zimmerman M, Trotter J. et al. Liver transplantation for primary biliary cirrhosis: results of aggressive corticosteroid withdrawal. Transplantation proceedings 2009; 41: 1707-1712
• 749 Neuberger J, Gunson B, Hubscher S. et al. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2004; 10: 488-491
• 750 Raczynska J, Habior A, Paczek L. et al. Primary biliary cirrhosis in the era of liver transplantation. Ann Transplant 2014; 19: 488-493
• 751 Charatcharoenwitthaya P, Pimentel S, Talwalkar JA. et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2007; 13: 1236-1245
• 752 Bosch A, Dumortier J, Boulch DM. et al. Long-term administration of ursodeoxycholic acid prevents recurrence of primary biliary cirrhosis after liver transplantation. J Hepatol 2015; 62: S783
• 753 MacQuillan GC, Neuberger J. Liver transplantation for primary biliary cirrhosis. Clin Liver Dis 2003; 7: 941-956, ix
• 754 Carbone M, Neuberger J. Liver transplantation in PBC and PSC: indications and disease recurrence. Clin Res Hepatol Gastroenterol 2011; 35: 446-454
• 755 Akamatsu N, Sugawara Y. Primary biliary cirrhosis and liver transplantation. Intractable Rare Dis Res 2012; 1: 66-80
• 756 Purohit T, Cappell MS. Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World journal of hepatology 2015; 7: 926-941
• 757 Registry ELT. Overall Indication and Results. http://eltreu/overall-indication-and-resultshtml
• 758 Organtransplantationsgesetz, Österreich BfGuF. Organtransplantationsgesetz. http://wwwbmgfgvat/cms/home/attachments/3/4/4/CH1517 / CMS1359975939403/otpg_bgbla_2012_i_108pdf
• 759 Transplantationsgesetz, Regierung BdS. Bundesgesetz über die Transplantation von Organen, Geweben und Zellen (Transplantationsgesetz). https://wwwadminch/opc/de/classified-compilation/20010918/201401010000/81021pdf
• 760 Bundesärztekammer. Statut der Ständigen Kommission Organtransplantation der Bundesärztekammer. 2014 http://wwwbundesaerztekammerde/fileadmin/user_upload/downloads/Staendige_Kommission_Organtransplantation_Statut_2014pdf
• 761 Tischendorf JJ, Meier PN, Strassburg CP. et al. Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis. Scand J Gastroenterol 2006; 41: 1227-1234
• 762 De Vreede I, Steers JL, Burch PA. et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl 2000; 6: 309-316
• 763 Heimbach JK, Gores GJ, Haddock MG. et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Seminars in liver disease 2004; 24: 201-217
• 764 O'Grady JG. Treatment options for other hepatic malignancies. Liver Transpl 2000; 6: S23-S29
• 765 Gores GJ, Nagorney DM, Rosen CB. Cholangiocarcinoma: is transplantation an option? For whom?. J Hepatol 2007; 47: 455-459
• 766 Ghouri YA, Mian I, Blechacz B. Cancer review: Cholangiocarcinoma. J Carcinog 2015; 14: 1
• 767 Petrowsky H, Hong JC. Current surgical management of hilar and intrahepatic cholangiocarcinoma: the role of resection and orthotopic liver transplantation. Transplantation proceedings 2009; 41: 4023-4035
• 768 Hoffmann RT, Paprottka PM, Schon A. et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 2012; 35: 105-116
• 769 Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2013; 11: 13-21 e1 ; quiz e3–4
• 770 Rea DJ, Heimbach JK, Rosen CB. et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Annals of surgery 2005; 242: 451-458 ; discussion 8–61
• 771 Sapisochin G, de Lope CR, Gastaca M. et al. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study. Annals of surgery 2014; 259: 944-952
• 772 DeOliveira ML. Liver transplantation for cholangiocarcinoma: current best practice. Current opinion in organ transplantation 2014; 19: 245-252
• 773 Vogel A, Wege H, Caca K. et al. The diagnosis and treatment of cholangiocarcinoma. Dtsch Arztebl Int 2014; 111: 748-754
• 774 Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013; 145: 1215-1229
• 775 Schmeding M, Neumann UP. Liver Transplant for Cholangiocarcinoma: A Comeback?. Exp Clin Transplant 2015; 13: 301-308
• 776 Esfeh JM, Eghtesad B, Hodgkinson P. et al. Duct-to-duct biliary reconstruction in patients with primary sclerosing cholangitis undergoing liver transplantation. HPB (Oxford) 2011; 13: 651-655
• 777 Pandanaboyana S, Bell R, Bartlett AJ. et al. Meta-analysis of Duct-to-duct versus Roux-en-Y biliary reconstruction following liver transplantation for primary sclerosing cholangitis. Transpl Int 2015; 28: 485-491
• 778 Goss JA, Shackleton CR, Farmer DG. et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Annals of surgery 1997; 225: 472-481 ; discussion 81–83
• 779 Sutton ME, Bense RD, Lisman T. et al. Duct-to-duct reconstruction in liver transplantation for primary sclerosing cholangitis is associated with fewer biliary complications in comparison with hepaticojejunostomy. Liver Transpl 2014; 20: 457-463
• 780 Wells MM, Croome KP, Boyce E. et al. Roux-en-Y choledochojejunostomy versus duct-to-duct biliary anastomosis in liver transplantation for primary sclerosing cholangitis: a meta-analysis. Transplantation proceedings 2013; 45: 2263-2271
• 781 Papatheodoridis GV, Hamilton M, Mistry PK. et al. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998; 43: 639-644
• 782 Kotlyar DS, Campbell MS, Reddy KR. Recurrence of diseases following orthotopic liver transplantation. The American journal of gastroenterology 2006; 101: 1370-1378
• 783 Graziadei IW, Wiesner RH, Marotta PJ. et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999; 30: 1121-1127
• 784 Narumi S, Roberts JP, Emond JC. et al. Liver transplantation for sclerosing cholangitis. Hepatology 1995; 22: 451-457
• 785 Fosby B, Karlsen TH, Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World journal of gastroenterology 2012; 18: 1-15
• 786 Graziadei IW. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2002; 8: 575-581
• 787 Hildebrand T, Pannicke N, Dechene A. et al. Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis. Liver Transpl 2016; 22: 42-52
• 788 Ravikumar R, Tsochatzis E, Jose S. et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol 2015; 63: 1139-1146
• 789 Li KK, Neuberger J. Recurrent nonviral liver disease following liver transplantation. Expert Rev Gastroenterol Hepatol 2009; 3: 257-628
• 790 Hoffmann JC, Preiss JC, Autschbach F. et al. Clinical practice guideline on diagnosis and treatment of Crohn's disease. Zeitschrift fur Gastroenterologie 2008; 46: 1094-1146
• 791 Joshi D, Bjarnason I, Belgaumkar A. et al. The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis. Liver international: official journal of the International Association for the Study of the Liver 2013; 33: 53-61
• 792 Jorgensen KK, Lindstrom L, Cvancarova M. et al. Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study. Scand J Gastroenterol 2012; 47: 1021-1029
• 793 Sandhu A, Alameel T, Dale CH. et al. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series. Aliment Pharmacol Ther 2012; 36: 159-165
• 794 Mohabbat AB, Sandborn WJ, Loftus Jr EV. et al. Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients. Aliment Pharmacol Ther 2012; 36: 569-574
• 795 Hanouneh IA, Macaron C, Lopez R. et al. Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis 2012; 18: 269-274
• 796 Singh S, Edakkanambeth Varayil J, Loftus Jr EV. et al. Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis. Liver Transpl 2013; 19: 1361-1369
• 797 Dehghani SM, Haghighat M, Imanieh MH. et al. Autoimmune hepatitis in children: experiences in a tertiary center. Iran J Pediatr 2013; 23: 302-308
• 798 Chai PF, Lee WS, Brown RM. et al. Childhood autoimmune liver disease: indications and outcome of liver transplantation. J Pediatr Gastroenterol Nutr 2010; 50: 295-302
• 799 Miloh T, Anand R, Yin W. et al. Pediatric liver transplantation for primary sclerosing cholangitis. Liver Transpl 2011; 17: 925-933
• 800 Venkat VL, Ranganathan S, Mazariegos GV. et al. Recurrence of primary sclerosing cholangitis in pediatric liver transplant recipients. Liver Transpl 2014; 20: 679-686
• 801 Yazigi NA. Long term outcomes after pediatric liver transplantation. Pediatr Gastroenterol Hepatol Nutr 2013; 16: 207-218
• 802 Floreani A, Liberal R, Vergani D. et al. Autoimmune hepatitis: Contrasts and comparisons in children and adults – a comprehensive review. J Autoimmun 2013; 46: 7-16
• 803 Czaja AJ. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transpl 2002; 8: 505-513
• 804 Harrison RF, Davies MH, Neuberger JM. et al. Fibrous and obliterative cholangitis in liver allografts: evidence of recurrent primary sclerosing cholangitis?. Hepatology 1994; 20: 356-361
• 805 Heffron TG, Smallwood GA, Oakley B. et al. Adult and pediatric liver transplantation for autoimmune hepatitis. Transplantation proceedings 2003; 35: 1435-1436
• 806 Andries S, Casamayou L, Sempoux C. et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. Transplantation 2001; 72: 267-272
• 807 Hadzic N, Quaglia A, Cotoi C. et al. Immunohistochemical phenotyping of the inflammatory infiltrate in de novo autoimmune hepatitis after liver transplantation in children. Pediatric transplantation 2012; 16: 501-510
• 808 Pongpaibul A, Venick RS, McDiarmid SV. et al. Histopathology of de novo autoimmune hepatitis. Liver Transpl 2012; 18: 811-818
• 809 Demetris AJ, Sebagh M. Plasma cell hepatitis in liver allografts: Variant of rejection or autoimmune hepatitis?. Liver Transpl 2008; 14: 750-755
• 810 Borso D, Lobermann M, Fritzsche C. et al. Vaccinations in patients with immunodeficiency or immunosuppressive therapy. Deutsche medizinische Wochenschrift 2013; 138: 145-150
• 811 RKI. Epidemiologisches Bulletin 24.08.2015/Nr. 34. Robert Koch-Institut; 2015: 327-362
• 812 Sester M, Gartner BC, Girndt M. et al. Vaccination of the solid organ transplant recipient. Transplantation reviews 2008; 22: 274-284
• 813 RKI. Epidemiologisches Bulletin 30.09.2005/Nr. 39. Robert Koch-Institut; 2005: 353-365
• 814 Arguedas MR, McGuire BM, Fallon MB. Implementation of vaccination in patients with cirrhosis. Digestive diseases and sciences 2002; 47: 384-387
• 815 Keeffe EB, Iwarson S, McMahon BJ. et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998; 27: 881-886
• 816 Keeffe EB, Krause DS. Hepatitis B vaccination of patients with chronic liver disease. Liver transplantation and surgery: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 1998; 4: 437-439
• 817 Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther 2004; 19: 715-727
• 818 Worns MA, Teufel A, Kanzler S. et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. The American journal of gastroenterology 2008; 103: 138-146
• 819 Dumot JA, Barnes DS, Younossi Z. et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. The American journal of gastroenterology 1999; 94: 1601-1604
• 820 Chalasani N, Smallwood G, Halcomb J. et al. Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation?. Liver transplantation and surgery: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 1998; 4: 128-132
• 821 Villeneuve E, Vincelette J, Villeneuve JP. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Canadian journal of gastroenterology = Journal canadien de gastroenterologie 2000; 14: 59b-62b
• 822 Wiedmann M, Liebert UG, Oesen U. et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 2000; 31: 230-234
• 823 McCashland TM, Preheim LC, Gentry MJ. Pneumococcal vaccine response in cirrhosis and liver transplantation. The Journal of infectious diseases 2000; 181: 757-760
• 824 Pirovino M, Lydick E, Grob PJ. et al. Pneumococcal vaccination: the response of patients with alcoholic liver cirrhosis. Hepatology 1984; 4: 946-949
• 825 Gaeta GB, Pariani E, Amendola A. et al. Influenza vaccination in patients with cirrhosis and in liver transplant recipients. Vaccine 2009; 27: 3373-3375
• 826 Gaeta GB, Stornaiuolo G, Precone DF. et al. Immunogenicity and safety of an adjuvanted influenza vaccine in patients with decompensated cirrhosis. Vaccine 2002; 20 (Suppl. 05) B33-B35
• 827 Soriano A, Nesher G, Shoenfeld Y. Predicting post-vaccination autoimmunity: who might be at risk?. Pharmacological research: the official journal of the Italian Pharmacological Society 2015; 92: 18-22
• 828 Della Corte C, Carlucci A, Francalanci P. et al. Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl. Vaccine 2011; 29: 4654-4656
• 829 Veerappan GR, Mulhall BP, Holtzmuller KC. Vaccination-induced autoimmune hepatitis. Digestive diseases and sciences 2005; 50: 212-213
• 830 Csepregi A, Treiber G, Rocken C. et al. Acute exacerbation of autoimmune hepatitis induced by Twinrix. World journal of gastroenterology 2005; 11: 4114-4116
• 831 Ghazale A, Chari ST, Zhang L. et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134: 706-715
• 832 de Buy Wenniger LJ, Culver EL, Beuers U. Exposure to occupational antigens might predispose to IgG4-related disease. Hepatology 2014; 60: 1453-1454
• 833 Alderlieste YA, van den Elzen BD, Rauws EA. et al. Immunoglobulin G4-associated cholangitis: one variant of immunoglobulin G4-related systemic disease. Digestion 2009; 79: 220-228
• 834 Kamisawa T, Funata N, Hayashi Y. et al. A new clinicopathological entity of IgG4-related autoimmune disease. Journal of gastroenterology 2003; 38: 982-984
• 835 Ghazale A, Chari ST, Smyrk TC. et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. The American journal of gastroenterology 2007; 102: 1646-1653
• 836 Oseini AM, Chaiteerakij R, Shire AM. et al. Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma. Hepatology 2011; 54: 940-948
• 837 Doorenspleet ME, Hubers LM, Culver EL. et al. Immunoglobulin G4(+) B-cell receptor clones distinguish immunoglobulin G 4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies. Hepatology 2016 64. 501-507 DOI: 10.1002/hep.28568 Epub 2016 Jun 8
• 838 Sah RP, Chari ST. Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis. Current opinion in rheumatology 2011; 23: 108-113
• 839 Nakazawa T, Naitoh I, Hayashi K. et al. Diagnosis of IgG4-related sclerosing cholangitis. World journal of gastroenterology 2013; 19: 7661-7670
• 840 Sugumar A, Levy MJ, Kamisawa T. et al. Endoscopic retrograde pancreatography criteria to diagnose autoimmune pancreatitis: an international multicentre study. Gut 2011; 60: 666-670
• 841 Cheuk W, Yuen HK, Chu SY. et al. Lymphadenopathy of IgG4-related sclerosing disease. The American journal of surgical pathology 2008; 32: 671-681
• 842 Okazaki K, Uchida K, Koyabu M. et al. IgG4 cholangiopathy – current concept, diagnosis, and pathogenesis. J Hepatol 2014; 61: 690-695
• 843 Kawakami H, Zen Y, Kuwatani M. et al. IgG4-related sclerosing cholangitis and autoimmune pancreatitis: histological assessment of biopsies from Vater's ampulla and the bile duct. Journal of gastroenterology and hepatology 2010; 25: 1648-1655
• 844 Sandanayake NS, Church NI, Chapman MH. et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2009; 7: 1089-1096
• 845 Joshi D, Webster GJ. Biliary and hepatic involvement in IgG4-related disease. Aliment Pharmacol Ther 2014; 40: 1251-1261
• 846 Hubers LM, Maillette de Buy Wenniger LJ, Doorenspleet ME. et al. IgG4-Associated Cholangitis: A Comprehensive Review. Clin Rev Allergy Immunol 2015; 48: 198-206
• 847 Nakazawa T, Ohara H, Sano H. et al. Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. Gastrointestinal endoscopy 2004; 60: 937-944
• 848 Huggett MT, Culver EL, Kumar M. et al. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. The American journal of gastroenterology 2014; 109: 1675-1683
• 849 Kamisawa T, Okazaki K, Kawa S. et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. Journal of gastroenterology 2014; 49: 961-970
• 850 Khosroshahi A, Wallace ZS, Crowe JL. et al. International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthritis Rheumatol 2015; 67: 1688-1699
• 851 Carruthers MN, Topazian MD, Khosroshahi A. et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Annals of the rheumatic diseases 2015; 74: 1171-1177
• 852 Hart PA, Topazian MD, Witzig TE. et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 2013; 62: 1607-1615
• 853 Miura H, Miyachi Y. IgG4-related retroperitoneal fibrosis and sclerosing cholangitis independent of autoimmune pancreatitis. A recurrent case after a 5-year history of spontaneous remission. JOP: Journal of the pancreas 2009; 10: 432-437
• 854 Stone JH, Zen Y, Deshpande V. IgG4-related disease. The New England journal of medicine 2012; 366: 539-551
• 855 Khosroshahi A, Stone JH. Treatment approaches to IgG4-related systemic disease. Current opinion in rheumatology 2011; 23: 67-71
• 856 Kamisawa T, Shimosegawa T, Okazaki K. et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1504-1507
• 857 Okazaki K, Kawa S, Kamisawa T. et al. Japanese clinical guidelines for autoimmune pancreatitis. Pancreas 2009; 38: 849-866
• 858 Maruyama M, Watanabe T, Kanai K. et al. Autoimmune pancreatitis can develop into chronic pancreatitis. Orphanet journal of rare diseases 2014; 9: 77
• 859 Hart PA, Kamisawa T, Brugge WR. et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut 2013; 62: 1771-1776
• 860 Yamamoto M, Nojima M, Takahashi H. et al. Identification of relapse predictors in IgG4-related disease using multivariate analysis of clinical data at the first visit and initial treatment. Rheumatology (Oxford) 2015; 54: 45-49
• 861 Kamisawa T, Zen Y, Pillai S. et al. IgG4-related disease. Lancet 2015; 385: 1460-1471
• 862 Khosroshahi A, Carruthers MN, Deshpande V. et al. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine 2012; 91: 57-66
• 863 Shiokawa M, Kodama Y, Yoshimura K. et al. Risk of cancer in patients with autoimmune pancreatitis. The American journal of gastroenterology 2013; 108: 610-617